Children's National Medical Center and Subsidiaries

Reports on Federal Awards in Accordance with the OMB Uniform Guidance June 30, 2021 Federal Entity Identification Number 52-1640403

Children's National Medical Center and Subsidiaries Index

June 30, 2021

	Page(s)
Part I - Financial Statements and Schedule of Expenditures of Federal Awards	
Report of Independent Auditors	1–2
Consolidated Balance Sheets	3–4
Consolidated Statements of Operations	5
Consolidated Statements of Changes in Net Assets	6
Consolidated Statements of Cash Flows	7
Notes to Consolidated Financial Statements	8–43
Supplementary Consolidating Information	
Report of Independent Auditors	44
Supplementary Consolidating Balance Sheet	45
Supplementary Consolidating Statement of Operations	46
Supplementary Consolidating Balance Sheet – The HSC Foundation and Subsidiaries	47
Supplementary Consolidating Statement of Operations – The HSC Foundation and Subs	idiaries48
Notes to Consolidating Supplementary Information	49
Schedule of Expenditures of Federal Awards	50–54
Notes to Schedule of Expenditures of Federal Awards	55
Part II - Reports on Compliance and Internal Control	
Report of Independent Auditors on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards	56–57
Report of Independent Auditors on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over Compliance in Accordance with the Uniform Guidance	
Part III - Findings	
Schedule of Findings and Questioned Costs	60–61
Summary Schedule of Prior Audit Findings	62

Part I Financial Statements and Schedule of Expenditures of Federal Awards Year Ended June 30, 2021



Report of Independent Auditors

To the Board of Trustees of Children's National Medical Center

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of Children's National Medical Center ("Children's National") and its subsidiaries, which comprise the consolidated balance sheets as of June 30, 2021 and 2020, and the related consolidated statements of operations, changes in net assets and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on the consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to Children's National's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Children's National's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Children's National and its subsidiaries as of June 30, 2021 and 2020, and the related consolidated statements of operations, changes in net assets and cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Other Matters

Other Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended June 30. 2021 is presented for purposes of additional analysis as required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance) and is not a required part of the consolidated financial statements. As described in Note 1 to the schedule of expenditures of federal awards, the accompanying schedule of expenditures of federal awards was prepared on the cash basis, which is a comprehensive basis of accounting other than accounting principles generally accepted in the United States of America. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, on the basis of accounting described in Note 2, in relation to the consolidated financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated October 8, 2021 on our consideration of Children's National's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended June 30, 2021. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Children's National's internal control over financial reporting and compliance.

Washington, D.C. October 8, 2021

Kricewaterhorsecroper up

Children's National Medical Center and Subsidiaries Consolidated Balance Sheets June 30, 2021 and 2020

(in thousands)	2021	2020
Assets		
Current assets		
Cash and cash equivalents	\$ 120,683	\$ 93,566
Short term investments	21,207	96,038
Short term assets whose use is limited	2,232	664
Accounts receivable, net	290,910	207,666
Settlements due from third-party payors	9,736	24,041
Contributions receivable, net	32,558	47,929
Grant receivable	11,879	15,659
Inventories of supplies	15,372	13,069
Prepaid expenses and other	44,512	40,939
Total current assets	549,089	539,571
Noncurrent assets		
Property and equipment, net	897,663	781,087
Right of use assets, financing	113,515	123,440
Right of use assets, operating	89,224	127,168
Assets whose use is limited	37,710	33,898
Investments	1,042,917	737,387
Contributions receivable, net	33,813	39,798
Loan receivable	13,496	13,496
Interest in beneficial trusts	9,762	7,188
Other	46,622	36,601
Total noncurrent assets	2,284,722	1,900,063
Total assets	\$ 2,833,811	\$ 2,439,634

Children's National Medical Center and Subsidiaries Consolidated Balance Sheets (continued) June 30, 2021 and 2020

(in thousands)	2021		2021	
Liabilities and Net Assets				
Current liabilities				
Accounts payable	\$	49,806	\$	69,409
Accrued salaries and other expenses		201,365		158,713
Current portion of reserve for claims		27,208		26,715
Settlements due to third-party payors		5,028		22,294
Deferred revenue		14,840		13,843
Medical claims payable		20,700		23,925
Current portion of long-term debt		11,303		13,858
Current portion of financing lease liabilities		7,946		4,525
Current portion of operating lease liabilities		7,717		7,656
Total current liabilities		345,913		340,938
Noncurrent liabilities				
Long-term debt		737,929		490,009
Long-term financing lease liabilities		139,536		143,962
Long-term operating lease liabilities		94,150		131,382
Reserve for claims		78,271		76,062
Interest rate swaps		-		60
Other long-term liabilities		44,853		35,338
Total noncurrent liabilities		1,094,739		876,813
Total liabilities		1,440,652		1,217,751
Net Assets				
Without donor restrictions - attributable to Children's National		983,327		869,859
Without donor restrictions - noncontrolling interests		7,366		7,592
Total net assets without donor restrictions		990,693		877,451
With donor restrictions		402,466		344,432
Total net assets		1,393,159		1,221,883
Total liabilities and net assets	\$	2,833,811	\$	2,439,634

Children's National Medical Center and Subsidiaries Consolidated Statements of Operations Years Ended June 30, 2021 and 2020

(in thousands)	2021	2020
Operating revenue and other support		
Net patient service revenue	\$ 1,127,080	\$ 1,091,416
Capitation revenue	176,260	150,782
Grant revenue	89,662	86,106
Other operating revenue	100,646	130,367
Contributions	25,528	22,455
Net assets released from restrictions used for operations	31,398	43,548
Total operating revenue and other support	1,550,574	1,524,674
Expenses		
Salaries, wages, and benefits	912,268	890,158
Supplies and other	406,281	395,072
Medical claims expense	83,853	90,496
Depreciation and amortization	93,084	78,911
Provision for insurance	16,971	20,472
Interest and amortization	29,310	19,981
Development expense	 22,927	 26,186
Total expenses	1,564,694	1,521,276
Operating (loss) income	(14,120)	3,398
Non-operating revenues and expenses		
Investment return, net	123,847	18,992
Realized and change in unrealized fair value of interest rate swaps	60	226
Inherent contribution from acquisition of HSC	-	98,542
Other non-operating income (loss), net	1,246	(281)
Total non-operating revenues and expenses	 125,153	117,479
Excess of revenues over expenses	111,033	120,877
Released from restriction for property and equipment	2,519	1,018
Other changes in net assets without donor restrictions	(310)	(270)
Increase in net assets without donor restrictions	\$ 113,242	\$ 121,625

Children's National Medical Center and Subsidiaries Consolidated Statements of Changes in Net Assets Years Ended June 30, 2021 and 2020

(in thousands)	2021		2020
Net assets without donor restrictions			
Excess of revenues over expenses	\$	111,033	\$ 120,877
Released from restriction for property and equipment		2,519	1,018
Other changes in net assets without donor restrictions		(310)	 (270)
Increase in net assets without donor restrictions		113,242	121,625
Net assets with donor restrictions		_	 _
Contributions		36,797	41,338
Investment return, net		58,846	7,664
Released from restrictions		(33,917)	(44,566)
Change in value of split interest agreements		2,574	(867)
Loss from uncollectible pledges		(6,426)	(357)
Other changes in net assets with donor restrictions		160	 1,263
Increase in net assets with donor restrictions		58,034	4,475
Change in net assets		171,276	 126,100
Net assets			
Beginning of year		1,221,883	 1,095,783
End of year	\$	1,393,159	\$ 1,221,883

Children's National Medical Center and Subsidiaries Consolidated Statements of Cash Flows Years Ended June 30, 2021 and 2020

(in thousands)		2021		2020
Cash flows from operating activities				
Change in net assets	\$	171,276	\$	126,100
Adjustments to reconcile change in net assets to net cash and cash				
equivalents provided by operating activities		02.004		70.044
Depreciation and amortization Provision for uncollectible contributions		93,084 6,241		78,911 106
Loss on sale of assets		36		281
Amortization of deferred financing costs		253		216
Amortization of bond premium		(2,420)		(2,584)
Loss in PSV equity investment		9,680		11,243
Inherent contribution from acquisition of HSC		-		(98,733)
Net realized and change in unrealized gains on investments		(159,583)		(14,020)
Change in fair market value of interest rate swaps Proceeds from restricted contributions and income received		(60) (9,923)		(33) (12,055)
Change in assets and liabilities		(9,923)		(12,055)
Accounts receivable for patient services		(83,244)		(1,106)
Settlements due from third-party payors		14,305		(11,198)
Other current assets and inventory of supplies		(5,876)		(3,597)
Contributions and grants receivable		18,895		16,554
Interest in beneficial trusts		(2,574)		867
Right-of-use assets		10,937		13,742
Other noncurrent assets		(9,826)		(1,982)
Accounts payable Accrued salaries and other expenses		(465) 42,652		(15,056) 37,545
Reserve for claims		2.702		6,879
Deferred revenue		997		(12,584)
Medical claims payable		(3,225)		2,037
Settlements due to third-party payors		(17,266)		10,036
Operating lease liabilities		(8,298)		(10,509)
Financing lease liabilities		664		-
Other noncurrent liabilities Net cash, cash equivalents, and restricted cash provided by operating activities		9,515 78,477		464 121,524
	_	10,411		121,024
Cash flows from investing activities		(462 670)		(400.035)
Purchases of property and equipment Proceeds from sales of property and equipment		(163,679) 309		(199,035)
Cash acquired through HSC member substitution		-		37,806
Purchases of investments		(651,163)		(668,975)
Sales of investments		576,606		710,933
Contribution to equity investment		(10,256)		(12,914)
Net cash, cash equivalents, and restricted cash used in investing activities		(248,183)		(132,185)
Cash flows from financing activities				
Proceeds from issuance of long-term debt		301,272		-
Proceeds from line of credit		2,000		50,000
Payments on line of credit		(2,000)		(50,000)
Payments of long-term debt Payments of debt issuance costs		(105,464) (2,791)		(6,766)
Proceeds from restricted contributions and income received		9,923		12,055
Proceeds from financing lease incentives		1,228		9,696
Payments on financing lease obligations		(5,787)		(2,476)
Net cash, cash equivalents, and restricted cash provided by financing activities		198,381		12,509
Increase in cash, cash equivalents, and restricted cash		28,675		1,848
Cash, cash equivalents, and restricted cash				
Beginning of year		94,176		92,328
End of year	\$	122,851	\$	94,176
Supplemental disclosure of cash flow information		_	_	_
Cash paid for interest	\$	26,876	\$	25,378
Property and equipment in accounts payable		(19,138)		27,980
Property and equipment in exchange for other long-term debt		54,515		-
The accompanying notes are an integral part of these consolidated	£:	-:-! -+-+		

The accompanying notes are an integral part of these consolidated financial statements.

1. Organization

Organizational Structure

The Children's National Medical Center's ("Children's National") consolidated financial statements include the accounts of Children's Hospital (the "Hospital"); Children's Hospital Foundation (the "Foundation"); Children's National at Walter Reed, LLC ("CNWR"); Children's Research Institute ("CRI"); Safe Kids Worldwide ("Safe Kids"); Children's Pediatricians and Associates ("CP&A"); Children's National Health Network ("CNHN"); Pediatric Health Network ("PHN"); Children's School Services ("CSS"); Brainy Camps Association ("BCA"); the HSC Foundation and Subsidiaries ("HSC"); Bearacuda Reinsurance Company, Ltd. (the "Captive"); Building 52/53 NMTC Borrower LLC; Building 52/53 HTC Tenant LLC; Building 54 Managing Member LLC; Building 54 NMTC Borrower LLC; Building 54 HTC Tenant LLC; Building 54 Managing Member LLC; all referred to as the "Subsidiaries."

Children's National is a tax-exempt, nonstock corporation, which controls its subsidiary corporations through its authority to appoint the governing boards of the tax-exempt, nonstock subsidiaries or its stock ownership. Children's National and its subsidiaries provide health care services to infants, children, and youth in Washington, D.C., and the surrounding metropolitan area. The Hospital operates an acute care pediatric and teaching facility.

The Foundation supports and maintains the programs, services, and facilities of Children's National in part through solicitation, receipt, administration, and distribution of philanthropic gifts on behalf of its tax-exempt subsidiaries.

CNWR is a limited liability company organized for the purpose of holding certain real property conveyed by the United States Department of Defense to be used for public health purposes.

CRI is a research organization involved in providing services and support in connection with the delivery of health care services on behalf of the community.

Safe Kids is an organization involved in nonhospital pediatric health and safety activities.

CP&A is a limited liability corporation that operates for-profit physician practices. CP&A is owned 50% by Children's National and 50% by the Hospital.

CNHN is a for-profit physician hospital organization, of which Children's National is the sole shareholder.

PHN is a for-profit clinically integrated physician network, of which Children's National is the sole shareholder.

CSS is an organization that operates a school nurse program in the District of Columbia.

BCA is an organization that provides residential summer camps, support, and leadership programs for youth with chronic health conditions, of which the Hospital is the sole corporate member.

The Captive is a wholly owned captive insurance company established to assume general liability and malpractice risk for Children's National entities, effective August 1, 1997.

Building 52/53 NMTC Borrower LLC ("Building 52/53 Borrower"), a Washington, D.C., limited liability company, was formed to acquire, own, rehabilitate, lease, manage, and operate the property known as Building 52/53 in a manner that will qualify such rehabilitation for historic and new market rehabilitation tax credits to Section 47 of the Internal Revenue Code of 1986, as amended. The property is comprised of

land and historic buildings located on the former campus of the Walter Reed Army Medical Center in Washington D.C. (the "WR Campus"). Building 52/53 is also located in a qualified census tract that meets certain income, unemployment and poverty level requirements and qualifies under the New Market Tax Credit Program as a qualified active low-income community business ("QALICB"). Through its ownership of Building 52/53 Managing Member LLC, CNMC holds a 90% interest in Building 52/53 Borrower. Building 52/53 Borrower follows a calendar based fiscal year.

Building 52/53 Managing Member LLC ("Building 52/53 MM"), a Washington D.C., limited liability company, is the managing member of Building 52/53 Borrower. Building 52/53 MM is a wholly owned subsidiary of Children's National and is taxed as a corporation. The member managers of Building 52/53 MM are officers and senior leaders of Children's National. As part of the New Market Tax Credit and Historic Tax Credit transactions, this separate, for-profit, single purpose entity was established to manage the Building 52/53 property to meet the QALICB requirements. Building 52/53 MM is the manager of the property and also the managing member of Building 52/53 HTC Tenant LLC, holding a 1% interest in Building 52/53 HTC Tenant LLC. Building 52/53 MM follows a calendar based fiscal year.

Building 52/53 HTC Tenant LLC ("Building 52/53 Tenant"), a Washington, D.C., limited liability company, was formed to lease, manage and operate property owned by Building 52/53 Borrower. Building 52/53 Tenant has made an equity investment in Building 52/53 Borrower and is also a member with a 10% interest. Building 52/53 Tenant consists of a managing member with 1% interest and an investor member with a 99% interest. Building 52/53 Tenant and Building 52/53 Borrower have executed a historic tax credit pass-through agreement pursuant to which Building 52/53 Borrower will elect under Section 50 of the Internal Revenue Code to pass through to Building 52/53 Tenant the federal tax credits to which it is entitled because of the historic building's rehabilitation project. Children's National meets the requirements for consolidation of the Building 52/53 Tenant through its ownership of the managing member (Building 52/53 MM) and control of Building 52/53 Tenant. The 99% interest held by an investor member is reflected as non-controlling interest. Building 52/53 Tenant follows a calendar based fiscal year.

Building 54 NMTC Borrower LLC ("Building 54 Borrower"), a Washington, D.C., limited liability company, was formed to acquire, own, rehabilitate, lease, manage, and operate the property known as Building 54 in a manner that will qualify such rehabilitation for historic rehabilitation tax credits pursuant to Section 47 of the Internal Revenue Code of 1986, as amended. The property is comprised of land and a historic building located on the WR Campus. Through its ownership of Building 54 Managing Member LLC, CNMC holds a 90% interest in Building 54 Borrower. Building 54 Borrower follows a calendar based fiscal year.

Building 54 Managing Member LLC ("Building 54 MM"), a Washington D.C., limited liability company, is the managing member of Building 54 Borrower. Building 54 MM is a wholly owned subsidiary of Children's National and is taxed as a corporation. The member managers of Building 54 MM are officers and senior leaders of Children's National. Building 54 MM is the manager of the property and also the managing member of Building 54 HTC Tenant LLC, holding a 1% interest in Building 54 HTC Tenant LLC. Building 54 MM follows a calendar based fiscal year.

Building 54 HTC Tenant LLC ("Building 54 Tenant"), a Washington, D.C., limited liability company, was formed to lease, manage and operate property owned by Building 54 Borrower. Building 54 Tenant has made an equity investment in Building 54 Borrower and is also a member with a 10% interest. Building 54 Tenant consists of a managing member with 1% interest and an investor member with a 99% interest. Building 54 Tenant and Building 54 Borrower have executed a historic tax credit pass-through agreement pursuant to which Building 54 Borrower will elect under Section 50 of the Internal Revenue Code to pass through to Building 54 Tenant the federal tax credits to which it is entitled because of the historic building's rehabilitation project. Children's National meets the requirements for consolidation of the Building 54

Children's National Medical Center and Subsidiaries Notes to Consolidated Financial Statements

Years Ended June 30, 2021 and 2020

Tenant through its ownership of the managing member (Building 54 MM) and control of Building 54 Tenant. The 99% interest held by an investor member is reflected as non-controlling interest. Building 54 Tenant follows a calendar based fiscal year.

Children's National, Hospital, Foundation, CRI, Safe Kids, CSS, and BCA are not-for-profit organizations that qualify under Section 501(c)(3) of the Internal Revenue Code, and are therefore, not subject to tax under current income tax regulations.

HSC Membership Substitution

On September 1, 2019, Children's National and HSC entered into an affiliation agreement whereby Children's National became the sole corporate member of the HSC. The affiliation between Children's National and HSC stems from a long-term business relationship and shared objective: to improve quality, access, and coordination of care for patients and families across the care continuum. The entities that comprise HSC are as follows:

The HSC Foundation, a nonprofit corporation is organized to coordinate the activities of and provide support to The Hospital for Sick Children (the "Pediatric Center") Health Services for Children with Special Needs, Inc ("HSCSN"), a managed care organization, HSC Services, LLC and 2013 Holdings, Inc.

The Pediatric Center is a Washington, D.C., nonprofit corporation, formed as a pediatric specialty care hospital.

HSCSN is a Washington, D.C., nonprofit corporation, formed as a health plan that services children and young adults who are residing in Washington, D.C. and qualify for the federal Supplemental Security Income program ("SSI") or a Tax Equity and Fiscal Responsibility Act ("TEFRA") wavier.

2013 Holdings, Inc. is a Washington, D.C. nonprofit corporation, formed as a real estate holding company, to hold title to certain real and personal property. 2013 Holdings, Inc. was dissolved effective June 30, 2020.

HSC Services, LLC is a Washington D.C., limited liability company, formed as an intermediary holding company between the HSC Foundation and HSC Home Care, LLC, a Washington, D.C., limited liability company, formed as a Medicare and Medicaid certified home health agency that provides care for children who have complex health care needs and disabilities.

No consideration was paid by Children's National to become the sole member of HSC. This transaction was accounted for using the acquisition method of accounting, which required all assets and liabilities of HSC to be revalued at their fair value as of the acquisition date. The acquisition date fair values have been determined using various fair value techniques including independent appraisals for property and equipment, quotations from independent market sources for investments and debt, and independent actuarial projections for workers compensation, medical claims payable, and medical malpractice liabilities. The fair value of HSC assets was larger than its liabilities; and therefore, inherent contributions received were recorded by Children's National of \$98.5 million.

The results of HSC's operations have been included in the statement of operations and changes in net assets commencing on the acquisition date. During the year ended June 30, 2020 excess of revenues of expenses attributable to HSC was \$3.3 million excluding the inherent contribution. The assets, liabilities, and net assets of HSC on September 1, 2019 were as follows:

Children's National Medical Center and Subsidiaries Notes to Consolidated Financial Statements

Years Ended June 30, 2021 and 2020

(in thousands)

Cash and cash equiavalents Accounts receivable, net Other current assets Property and equipment, net	\$ 37,648 11,513 8,865 33,194
Investments Other assets	64,344 9,854
Total assets assumed	\$ 165,419
Accounts payable and other current liabilities Medical claims payable Long-term debt Other liabilities	26,980 21,888 8,415 9,402
Total liabilities assumed	\$ 66,685
Contribution without donor restrictions received Contribution with donor restrictions received	98,542 191
Total contribution received	\$ 98,733

The following table represents Children's National's proforma financial information as of June 30, 2020 assuming the acquisition of HSC had taken place on July 1, 2019. The proforma financial information may not be indicative of the actual results of operations if the transaction had been effective on July 1, 2019.

(in thousands)	2020
Revenues	\$ 1,550,793
Expenses	1,547,746
Operating income	3,047
Nonoperating gains	19,443
Excess of revenues over expenses	22,490

2. Risk Factors

Children's National's ability to maintain or increase future revenues could be adversely impacted by: (1) future legislation, regulation, or other actions by federal, state, or District of Columbia agencies, which may impose requirements or continue the trend toward more restrictive limitations on reimbursement for hospital services; (2) future legislation or adverse trends affecting the costs related to professional liability coverage; (3) changes in general and local economic conditions including the financial condition of the District of Columbia, the State of Maryland and the State of Virginia; and (4) a potential shortage of qualified doctors and other skilled healthcare professionals in the local employment market.

In December 2019, a novel strain of coronavirus, Coronavirus Disease 2019 ("COVID-19"), developed and has spread around the world, with resulting business and social disruption. Recent actions taken by Children's National to combat the spread COVID-19 have had an adverse effect on Children's National's operations. The extent to which COVID-19 impacts the operations of Children's National in the future will depend on the duration and severity of the outbreak as well Children's National's ability to contain its impact. These developments cannot be predicted with confidence and could have a negative effect on the current financial results of Children's National, including its operations and its investments. If the duration of the outbreak becomes extended or increases in severity, Children's National has available liquidity, as well as the ability to adjust capital expenditures and curtail certain discretionary operating expenses to mitigate the impact of COVID-19 on operating results.

In April 2020, the Department of Health and Human Services ("HHS") began distributing portions of its \$175 billion stimulus funding appropriation to providers in response to the COVID-19 pandemic. In order to keep the distributed funds, provider relief payments require an attestation indicating that the recipient agrees to comply with certain terms and conditions, including use of the funds to offset lost revenues and increased expenses that have resulted from the pandemic. In addition to providing relief through a general allocation to most providers, HHS also distributed funding for targeted purposes, including to hospitals in "high impact" areas, in rural areas, and those considered "safety net" hospitals for uninsured patients. Children's National accounted for the provider relief funds using the contribution model of accounting. All terms and conditions of the relief fund award were met to recognize revenue and therefore, Children's National recorded \$27.2 million and \$53.0 million in other operating revenue in the accompanying Consolidated Statement of Operations for the year ended June 30, 2021 and 2020, respectively.

3. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

Principles of Consolidation

The consolidated financial statements include the accounts of Children's National and its subsidiaries after elimination of all significant intercompany accounts and transactions.

Cash and Cash Equivalents

Cash equivalents include amounts invested in accounts with depository institutions which are readily convertible to cash, with original maturities of three months or less. Total deposits maintained at these institutions at times exceed the amount insured by federal agencies and therefore, bear a risk of loss. Children's National has not experienced such losses on these funds.

Children's National Medical Center and Subsidiaries

Notes to Consolidated Financial Statements

Years Ended June 30, 2021 and 2020

Investments and Assets Whose Use is Limited

Investments consist primarily of money market funds, government securities, equity securities (including common trust funds), and mutual funds and are reported at fair value. Investments that management does not consider necessary for current operations are classified as long-term.

Investments in companies in which Children's National does not have control but has the ability to exercise significant influence over operating and financial policies are accounted for under the equity method of accounting and operating results are recorded within investment return, net on the Consolidated Statements of Operations. Dividends received are recorded as a reduction of the carrying amount of the investment.

Assets whose use is limited include cash and investments restricted under professional liability arrangements and debt agreements.

Restricted cash amounts included in short term assets whose use is limited represent amounts required to be set aside by debt or regulatory agreements. Restricted cash amounts included in assets whose use is limited represent amounts set aside to pay general and professional liability claims.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets to the amounts shown in the Consolidated Statements of Cash Flows as of June 30:

(in thousands)	2021			2020		
Cash and cash equivalents	\$	120,683	\$	93,566		
Short term assets whose use is limited		1,577		156		
Assets whose use is limited		591		454		
Cash, cash equivalents, and restricted cash	\$	122,851	\$	94,176		

Investment Income

Investment income or loss including interest and dividends, net of investment management fees; realized gains and losses on investments; and unrealized gains and losses on equity securities is reported as non-operating revenue and is included in excess of revenue over expenses unless the income or loss is restricted by donor or law.

Income Taxes

Children's National is a not-for-profit corporation as described in Section 501(c)(3) of the Internal Revenue Code and is exempt from federal income taxes on related income pursuant to Section 501(a) of the Code. On such basis, the exempt entities will not incur any liability for federal income taxes, except for possible unrelated business income.

The Financial Accounting Standards Board's ("FASB") guidance on accounting for uncertainty in income taxes clarifies the accounting for uncertainty of income tax positions. The guidance defines the threshold for recognizing tax return positions in the consolidated financial statements as "more likely than not" that the position is sustainable, based on technical merits.

Children's National evaluates uncertain tax positions using a two-step approach for recognizing and measuring tax benefits taken or expected to be taken in an unrelated business activity tax return and disclosures regarding uncertainties in tax positions. There was no impact on Children's National's consolidated financial statements during the years ended June 30, 2021 and 2020, as Children's National has no uncertain tax positions.

Children's National Medical Center and Subsidiaries Notes to Consolidated Financial Statements

Years Ended June 30, 2021 and 2020

Accounts Receivable, net

Patient accounts receivable consists primarily of amounts owed by various governmental agencies, insurance companies and patients. Children's National manages these receivables by regularly reviewing the accounts and contracts and by recording appropriate price concessions. Children's National reports accounts receivable at an amount equal to the consideration it expects to receive in exchange for providing healthcare services to its patients, which is estimated using contractual provisions associated with specific payors, historical reimbursement rates and analysis of past experience to estimate potential adjustments. Children's National writes off amounts that have been deemed to be uncollectible because of circumstances that affect the ability of payors to make payments as they occur.

Inventories of Supplies

Inventories generally consist of medical and nonmedical supplies and are stated at the lower of cost or net realizable value, using the first-in, first-out method. The total inventory balance was \$15.4 million and \$13.1 million at June 30, 2021 and 2020, respectively.

Contributions and Grants

Unconditional promises to give cash and other assets are reported at fair value as contributions receivable at the date the promise is received. These promises are subject to annual donor approval and are restricted. Amounts due are recorded at the net realizable value discounted using a rate of return that a market participant would expect to receive over the payment period at the date the pledge is received. An allowance for uncollectible pledges is recorded for pledges which may become uncollectible in future periods. Amounts deemed to be uncollectible have been written off. The contributions receivable balance is based on management's best estimate of the amounts expected to be collected. The amounts Children's National will ultimately realize could differ from the amounts assumed in arriving at the present value and allowance for doubtful pledges. Conditional promises to give and indications of intentions to give are reported at fair value at the date the promise becomes unconditional. As of June 30, 2021 and 2020 conditional promises to give excluding those from grants, amounted to \$44.7 million and \$49.4 million, respectively.

The gifts are reported as net assets with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is met, net assets with donor restrictions are reclassified as net assets without donor restrictions and reported in the Consolidated Statements of Operations as net assets released from restrictions used for operations. Donor-restricted contributions whose restrictions are met within the same year as received are reported as net assets without donor restrictions in the accompanying consolidated financial statements.

Children's National and its subsidiaries receive various grants from Federal agencies and District of Columbia agencies for the purpose of furthering its mission of providing acute pediatric care, research and education. For the majority if its grants, Children's National accounts for them under the contribution model, which is outside the scope of ASC 606, *Revenue from Contracts with Customers* ("ASC 606"). Revenue for these grants is recognized as expenses are incurred. Grants recognized under ASC 606 were \$30.0 million and \$29.6 million in the years ended June 30, 2021 and 2020, respectively.

Total conditional contributions from grants as of June 30, 2021 and 2020 were \$62.8 million and \$61.2 million, respectively. Revenue for these conditional contributions will be recognized in future periods when the conditions are met. The conditions related to these contributions are based on performance barriers, a right of return, and scope related conditions as outlined under the Uniform Guidance cost principles. Children's National has elected the simultaneous release option which allows a conditional restricted contribution to be recognized directly in net assets without donor restrictions if the condition and restriction is met in the same period that the revenue is recognized.

Children's National Medical Center and Subsidiaries

Notes to Consolidated Financial Statements

Years Ended June 30, 2021 and 2020

Loan Receivable

As part of the New Market Tax Credit and Historic Tax Credit transactions, Children's Hospital made a leveraged loan to Children's National NMTC Investment Fund, LLC in the amount of \$13.5 million in June 2019. The loan bears interest at 1.3% with quarterly interest only payments due September 2019 through March 2026, followed by quarterly principal and interest payments of \$160 thousand through June 2049.

New Accounting Pronouncements

In August 2018, the FASB issued ASU 2018-13, *Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement* ("ASU 2018-13"). ASU 2018-13 is intended to improve the effectiveness of disclosure requirements on fair value measurement. Amongst other changes, ASU 2018-13 removes: i) the requirement to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, ii) the requirement to disclose the policy for timing of transfers between levels, and iii) disclosure of the valuation processes for Level 3 fair value measurements. In addition, ASU 2018-13 modifies the disclosure requirements to require disclosure for investments in certain entities that calculated net asset value of the timing of liquidation of an investee's assets and the date redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly and clarifies that the measurement uncertainty disclosure is to communicate information about the uncertainty of measurement as of the reporting date. The update is effective for fiscal years, and interim periods with those fiscal years, beginning after December 15, 2019 with early adoption permitted. An entity is permitted to early adopt any removed or modified disclosures upon the issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. Children's National adopted ASU 2018-13 during 2021 and modified its disclosures accordingly.

Property and Equipment

Property and equipment acquisitions are recorded at cost. Depreciation expense on Children's National's property and equipment is recorded using the straight-line method, which allocates the cost of the tangible property equally over the estimated useful lives, beginning with the date the asset is placed in service. Below are the useful lives by asset category:

Buildings	25 - 40 years
Building improvements	9 - 20 years
Fixed equipment	10 - 15 years
Movable equipment	3 - 20 years

Interest cost incurred on borrowed funds during the period of construction of capital assets is capitalized as a component of the cost of acquiring those assets, net of any income earned. Repairs and maintenance are expensed as incurred. When property and equipment are retired, sold or otherwise disposed of, the asset's carrying amount and related accumulated depreciation are removed from the accounts and any gain or loss is recognized.

Deferred Financing Costs

Financing costs incurred in connection with the issuance of long-term debt are deferred and amortized using the straight-line method, which approximates the effective interest rate method, over the period of time the debt is outstanding. Deferred financing costs are recorded in long-term debt on the Consolidated Balance Sheets. The amortization expense was approximately \$0.3 million and \$0.2 million for the years ended June 30, 2021 and 2020, respectively.

Impairment of Long-Lived Assets

Long-lived assets are reviewed for impairment when events and circumstances indicate that the carrying amount of an asset may not be recoverable. Children's National's policy is to record an impairment loss when it is determined that the carrying amount of the asset exceeds the sum of the expected undiscounted future cash flows resulting from the use of the asset and its eventual disposition. Impairment losses are

measured as the amount by which the carrying amount of the asset exceeds its fair value. Long-lived assets to be disposed of are reported at the lower of the carrying amount or fair value less cost to sell. There were no impairments of long-lived assets for the years ended June 30, 2021 and 2020.

Interest in Beneficial Trusts

Children's National also receives contributions in the form of irrevocable split-interest agreements. These agreements include charitable remainder trusts, charitable gift annuities and perpetual trusts. In all of these agreements, Children's National has an interest in the trust, but is not the trustee. When the trust's obligations to all beneficiaries expire, the remaining assets revert to Children's National to be used according to the donor's wishes.

Deferred Compensation Plan

Children's National maintains a deferred compensation plan for certain employees. As of June 30, 2021 and 2020, deferred compensation investments of \$40.8 million and \$31.0 million, respectively, included in other assets on the Consolidated Balance Sheets, represent investments held by Children's National under these deferred compensation agreements. Such amounts approximate Children's National's related liability to the employees and are included in other long-term liabilities.

Interest Rate Swaps

The value of the interest rate swap agreements entered into by Children's National is adjusted to fair value monthly at the close of each accounting period based upon quotations from market makers. The change in fair value, if any, is recorded in the Consolidated Statements of Operations. Entering into interest rate swap agreements involves, to varying degrees, elements of credit, default, prepayment, market and documentation risk in excess of the amounts recognized on the Consolidated Balance Sheets. Such risks involve the possibility that there will be no liquid market for these agreements, the counterparty to these agreements may default on its obligation to perform and there may be unfavorable changes in interest rates.

Net Assets

Net assets without donor restrictions include undesignated amounts as well as amounts designated by the board for future capital and operating purposes. Net assets with donor restrictions are those whose use by Children's National has been limited by donors to a specific time period or purpose, including federal appropriations restricted for capital improvements. Net assets are released from donor restriction by incurring expenses satisfying the restricted purpose or by occurrence of the passage of time or other events specified by donors. Also included in net assets with donor restrictions are those gifts that have been restricted by donors to be maintained by Children's National in perpetuity.

Charity Care

Children's National, in keeping with its mission and philosophy to extend quality care and compassionate service, recognizes that some patients are unable to compensate Children's National for their treatment either through third party coverage or their own resources. Accordingly, Children's National extends charity or free care to those patients who do not have the ability to meet their obligations. Children's National provides free care based on federal poverty income guidelines or when it is determined that the patients are unable to fulfill their obligations to Children's National. Children's National also provides assistance in helping patients obtain third party coverage through state Medicaid programs. Because Children's National does not pursue collections of amounts determined to qualify as charity care, they are not reported as revenue. Direct and indirect costs for these services amounted to \$5.4 million and \$7.6 million for the years ended June 30, 2021 and 2020, respectively. The costs of providing charity care services are based on a calculation which applies a ratio of costs to charges to the gross uncompensated charges associated with providing care to charity patients. The ratio of cost to charge is calculated based on Children's National's total operating expenses divided by patient service revenue.

Children's National Medical Center and Subsidiaries

Notes to Consolidated Financial Statements

Years Ended June 30, 2021 and 2020

In addition to direct charity care, Children's National is committed to improving the health and well-being of children in the Washington, D.C., metropolitan area. Through programs of clinical intervention, community awareness, education and advocacy, Children's National strives to address the many challenges facing children and families today. Examples of programs addressing these challenges are the Community Pediatric Health Care Centers, school nursing services for District of Columbia Public Schools and District of Columbia Public Chartered Schools, Team Kid Power ("KIPOW"), DC Collaborative for Mental Health in Pediatric Primary Care, Health Access in Pediatrics ("DC MAP") Program, and services provided to children with AIDS.

Excess of Revenues Over Expenses

The Consolidated Statements of Operations include excess of revenues over expenses. Changes in net assets without donor restrictions which are excluded from excess of revenues over expenses, consistent with industry practice, include, among other items, contributions released from restrictions for property and equipment.

Use of Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting period. Actual results could differ from these estimates. These significant estimates include, among others, estimated net realizable value of patient receivables, estimated third-party payor settlements, and accrued insurance costs.

Accrued Vacation

Children's National records a liability for amounts due to employees for future absences which are attributable to services performed in the current and prior period. The liability for accrued vacation was \$37.5 million and \$36.4 million as of June 30, 2021 and 2020, respectively, and is recorded in accrued salaries and other expenses.

Estimated Malpractice Costs

The provision for estimated medical malpractice claims includes estimates of the ultimate costs for both reported claims and claims incurred but not reported.

Reserve for Medical Malpractice Claims

Children's National's medical malpractice claims reserve is an estimate of payments to be made for claims losses incurred but not reported. The estimate was developed using actuarial methods based upon historical data for payment patterns, cost trends, and other relevant factors. The estimate is continually reviewed and adjusted as necessary as experience develops or new information becomes known, such adjustments are included in current operations.

Medical Claims Expense and Payable

HSCSN contracts with various health care providers for the provision of related medical care services to its members. The providers are compensated based on payment rates as specified in the provider agreements. Medical claims expense that has been reported in the accompanying Consolidated Statements of Operations includes an accrual for medical services incurred but not reported ("IBNR"). Medical claims expense is determined using a combination of methods including multiplying census times average daily rate for inpatient facilities, per-member-per-month for medical categories other than inpatient and, actual invoices for pharmacy and other vendors. IBNR is determined using the percentage of completion model analysis which uses paid claims to estimate the total dollar of claims outstanding at a given point in time.

Net Patient Service Revenue

Net patient service revenue is reported at the amount that reflects the consideration to which Children's National expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors (including health insurers and government programs), and others. Generally, Children's National bills the patient and third-party payors several days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by Children's National. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected or actual charges. Children's National believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients receiving inpatient acute care services. Children's National measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided, and Children's National does not believe it is required to provide additional goods or services to the patient.

Because all of its performance obligations relate to contracts with a duration of less than one year, Children's National has elected to apply the practical expedient provided in FASB ASC 606-10-50-14a, and therefore is not required to disclose the aggregate amounts of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. These performance obligations are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. Children's National also provides services to uninsured patients. The transaction price for both uninsured patients, as well as insured patients with deductibles and coinsurance, is estimated based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts and implicit price concessions. Children's National determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Children's National determines its estimate of implicit price concessions based on historical collection experience with these classes of patients using a portfolio approach as a practical expedient. The portfolio approach is being used as Children's National has a large volume of similar contracts with similar classes of customers. Management's judgment to group the contracts by portfolio is based on the payment behavior expected in each portfolio category. Children's National reasonably expects that the effect of applying a portfolio approach to a group of contracts would not differ materially from considering each contract separately.

Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of change. No significant amounts of revenues were recognized in the current year due to changes in the estimates of implicit price concessions, discounts and contractual adjustments for performance obligations satisfied in the prior years. Subsequent changes that are determined to be the results of an adverse change in the patient's or third party payor's ability to pay are recorded as bad debt expense. Bad debt expense is reported as a component of supplies and other in the Consolidated Statements of Operations and Changes in Net Assets and was not significant for the years ended June 30, 2021 and 2020.

Children's National has agreements with third-party payors that provide for payments to Children's National at amounts different from its established rates. Payment arrangements include prospectively determined rates per discharge, reimbursed cost, discounted charges, and per diem payments. Contractual adjustments to patient service revenue were \$1.8 billion and \$1.6 billion for the years ended June 30, 2021 and 2020, respectively.

Approximately 43% and 47% of net patient service revenues were from Medicaid and Medicaid managed care programs in 2021 and 2020, respectively. Total reimbursements received for Graduate Medical Education ("GME") were \$16.5 million in 2021 and \$17.9 million in 2020. Federal GME is subject to appropriation each year.

Inpatient and outpatient services, defined capital and medical education costs related to beneficiaries are paid using a cost reimbursement methodology for Medicare and the Fee-for-Service Medicaid programs. These services are paid prospectively for DC Medicaid and Maryland Medicaid. For cost reimbursable items, Children's National is reimbursed at a tentative rate with final settlement determined after submission of the annual cost reports by Children's National and audits thereof by the fiscal intermediary. Children's National cost reports have been audited and settled by the Medicare intermediary through 2019 for all facilities. The Virginia Medicaid cost report is settled annually and is settled through 2020.

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to interpretation. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge Children's National's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon Children's National. In addition, the contracts Children's National has with commercial payors also provide for retroactive audit and review of claims.

Cost report settlements under reimbursement agreements with Medicare and Medicaid for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and Children's National's historical experience. Estimated settlements are adjusted in future periods as final settlements are determined. There is a reasonable possibility that recorded estimates will change by a material amount in the near term. Adjustments arising from a change in the transaction price were not significant in 2021 and 2020.

The composition of net patient service revenues by payor for the years ended June 30, is as follows:

(in thousands)	2021		'in thousands)		2020
Blue Cross	\$	265,110	\$ 239,602		
Commercial		12,608	6,420		
Managed Care		308,356	306,990		
Medicaid		489,002	512,002		
Other		34,155	22,073		
Self-pay		17,849	 4,329		
Total	\$	1,127,080	\$ 1,091,416		

Children's National has elected the practical expedient allowed under FASB ASC 606-10-32-18 and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to Children's National's expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. However, Children's National does, in certain instances, enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract.

Capitation Revenue and Receivable

HSCSN receives a monthly interim capitation rate per enrollee and recognizes capitation revenue from premiums in the period that a member is eligible for health care coverage. Revenue related to capitation premiums consists of the amount the District of Columbia has contracted to pay for the provision of health care benefits. HSCSN has accrued the difference between the actual monthly interim payment and the estimated reimbursement for the actual monthly enrollee population served.

HSCSN entered into a Child and Adolescent Supplemental Security Income Program ("CASSIP") agreement with the District of Columbia Department of Health Care Finance ("DHCF") to coordinate health care services for a defined group of Supplemental Security Income-eligible special needs children and youths. This indefinite-delivery indefinite-quantity contract is HSCSN's primary source of operating revenue. Under this agreement, DHCF pays HSCSN a fixed capitation amount based on the number of eligible participants enrolled in the program, subject to a final retroactive settlement. The contract requires an annual settlement process whereby DHCF and HSCSN share the benefits and risks associated with financial gains and losses of the managed care program, which are final settled through December 31, 2017. These amounts are included in due to third-party payers in the accompanying Consolidated Balance Sheets.

The capitation payment received by HSCSN has two components: one for administrative services and the second for medical services. The administrative services portion funds the management expenses of HSCSN, as well as the annual premium tax assessed by the District of Columbia, and factors in the potential for a 2% margin. The medical services portion pays for medical services (physician, hospital, pharmacy, home health, etc.), case management, utilization management, and quality oversight services.

The capitation payment is calculated based on the target medical claims ratio, which is the aggregate claims paid for the year for services covered, and medical management expenses as determined by Maryland's COMAR regulations. This medical services portion of HSCSN's capitation payment is subject to a risk sharing arrangement. If the total costs for medical services differs from the threshold specified in the CASSIP agreement, then the over/under outside of the base 2% corridor is shared between HSCSN and DHCF on a sliding scale, where HSCSN is at risk for a proportion of the overage for 50% or 100%, or benefits from the underage at a similar proportion.

HSCSN's third party receivables and payables result from this single contract with the DHCF. Termination of the contract or non-payment by the DHCF of the capitation revenue or risk receivable would have a material adverse effect on future operations and the liquidity of HSCSN. The current contract with DHCF expires in March 2022.

HSCSN's ability to maintain and/or increase future revenue could be adversely affected by: (1) the growth of managed care organizations promoting alternative methods for health care delivery and payment of services such as discounted fee for service networks and capitated fee arrangements; (2) proposed and/or future changes in the laws, rules, regulations, and policies relating to the definition, activities, and/or taxation of not-for-profit tax-exempt entities; (3) the inability of the District of Columbia, Maryland and Virginia Medicaid programs to correctly process medical claims and ultimately pay the System for services it provides to their patients; (4) the inability to collect on revenue earned for services provided; and (5) possible changes in general and local economic conditions, which could cause volatility in and/or limitations to access to capital and debt markets.

Other Revenue

In addition to net patient service and capitation revenue, Children's National also recognizes revenue related to other transactions. These transactions include revenues from parking, pharmacy 340b programs, collaborative arrangements with other healthcare providers, transport and PSV. Revenue from these transactions is recognized when obligations under the terms of the respective contract are satisfied. Revenue from these transactions is measured as the amount of consideration Children's National expects to receive from those services.

4. Fair Value Measurements

Children's National follows the FASB's guidance on fair value measurements, which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, establishes a framework for measuring fair value, and expands disclosures about such fair value measurements. This guidance applies to other accounting pronouncements that require or permit fair value measurements, and accordingly, this guidance does not require any new fair value measurements.

The guidance discusses valuation techniques such as the market approach, cost approach and income approach. This guidance establishes a three-tier level hierarchy for fair value measurements based upon the transparency of inputs used to value an asset or liability as of the measurement date.

The three-tier hierarchy prioritizes the inputs used in measuring fair value as follows:

- Level 1 Observable inputs such as quoted market prices for identical assets or liabilities in active markets;
- Level 2 Observable inputs for similar assets or liabilities in an active market, or other than quoted prices in an active market that are observable either directly or indirectly; and
- Level 3 Unobservable inputs in which there is little or no market data that require the reporting entity to develop its own assumptions.

The financial instrument's categorization within the hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Each of the financial instruments below has been valued utilizing the market approach.

The following tables present the financial instruments carried at fair value grouped by hierarchy level:

(in thousands)	June 30, 2021					
	Quoted In Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		ı	Total Fair Value
Assets						
Investments						
Cash and short term investments	\$	52,005	\$	-	\$	52,005
Fixed income securities		374,506		35,896		410,402
Equity securities		622,166		425		622,591
Real estate investments				6,125		6,125
Total investments		1,048,677		42,446		1,091,123
Deferred compensation money market funds		2,035		-		2,035
Deferred compensation mutual funds		38,771		-		38,771
Beneficial interests held by 3rd party		-		1,145		1,145
Perpetual trusts held by 3rd party		-		8,617		8,617
Short term assets whose use is limited						
by terms of debt agreement		2,232				2,232
Total assets at fair value	\$	1,091,715	\$	52,208	\$	1,143,923
Investment funds at NAV						4,427
					\$	1,148,350
Liabilities						
Deferred compensation liability	\$		\$	42,007	\$	42,007
Total liabilities at fair value	\$		\$	42,007	\$	42,007

22

(in thousands)	Quoted	e 30, 2020 gnificant Other		
	In Active Markets (Level 1)	servable Inputs Level 2)	F	Total air Value
Assets				
Investments				
Cash and short term investments	\$ 153,135	\$ -	\$	153,135
Fixed income securities	313,659	42,524		356,183
Equity securities	342,782	425		343,207
Real estate investments	 -	 6,125		6,125
Total investments	809,576	49,074		858,650
Deferred compensation money market funds	2,605	-		2,605
Deferred compensation mutual funds	27,170	-		27,170
Beneficial interests held by 3rd party	-	783		783
Perpetual trusts held by 3rd party	-	6,405		6,405
Short term assets whose use is limited				
by terms of debt agreement	664	 		664_
Total assets at fair value	\$ 840,015	\$ 56,262	\$	896,277
Investment funds at NAV				2,965
			\$	899,242
Liabilities				
Deferred compensation liability	\$ -	\$ 31,037	\$	31,037
Interest rate swaps		 60		60
Total liabilities at fair value	\$ -	\$ 31,097	\$	31,097

The following tables present information for investments measured at net asset value ("NAV") as of June 30:

(in thousands) Description	-	NAV at e 30, 2021	Redemption frequency	Redemption notice period	Receipt of proceeds	June 30, 2021 unfunded commitments
Limited partnerships	\$	1,240	Ranges from illiquid to quarterly	60 days	Ranges from 95% on redemption date, to within 3 years of redemption date	3,784
Funds of funds	\$	3,187 4,427	Ranges from monthly to annually	Ranges from 5 to 65 days	Ranges from 95% on redemption date, to within one year of redemption date	\$407

(in thousands)		IAV at	Redemption	Redemption	Descript of proceeds	June 30, 2020 unfunded
Description	June	30, 2020	frequency	notice period	Receipt of proceeds	commitments
Limited partnership	\$	84	Ranges from illiquid to quarterly	60 days	Ranges from 95% on redemption date, to within 3 years of redemption date	None
Funds of funds	\$	2,881 2,965	Ranges from monthly to annually	Ranges from 5 to 65 days	Ranges from 95% on redemption date, to within one year of redemption date	\$427

Following is a description of the Children's National valuation methodologies for assets and liabilities measured at fair value.

Fair value for Level 1 is based upon quoted prices in active markets that Children's National has the ability to access for identical assets and liabilities. Market price data is generally obtained from exchange or dealer markets. Children's National does not adjust the quoted price for such assets and liabilities. Level 1 investments include cash and cash equivalents including money market accounts, fixed income and equity securities, and mutual funds that are traded in an active exchange market. Cash equivalents are considered short term investments.

Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Inputs are obtained from various sources including market participants, dealers, and brokers. Level 2 investments include certain equity mutual funds, real estate investments, corporate bond funds, US government obligations, and federal agency obligations.

Certain investments are measured at NAV, which consist of limited partnerships and fund of funds. The limited partnerships represent domestic and offshore private placement securities. The fund of funds are investment funds, which invest in other investment funds to reach their desired investment objectives. The master funds are investment funds, which invest substantially all of their assets through a "master feeder" structure to pool investment capital raised by both U.S. and overseas investors into one central vehicle. The investment fund investments have varying liquidity terms from illiquid to annual liquidity.

Interest rate swaps are valued using both observable and unobservable inputs, such as quotations received from the counterparty, dealers or brokers, whenever available and considered reliable. In instances where models are used, the value of the interest rate swap depends upon the contractual terms of, and specific risks inherent in, the instrument as well as the availability and reliability of observable inputs. Such inputs include market prices for reference securities, yield curves, credit curves, measures of volatility, prepayment rates, assumptions for nonperformance risk, and correlations of such inputs. The interest rate swap arrangements have inputs which can generally be corroborated by market data and are therefore classified within Level 2.

The fair value of the obligations under deferred compensation agreements approximates the fair value of the other investment assets, which are determined using quoted market prices. These assets are comprised of mutual funds and money market funds.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while Children's National believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

5. Property and Equipment

The components of property and equipment as of June 30 are summarized below:

(in thousands)	2021	2020
Land	\$ 37,651	\$ 27,506
Buildings and building improvements	1,345,936	986,842
Fixed and movable equipment	380,542	 320,378
	1,764,129	1,334,726
Less: Accumulated depreciation	 (939,210)	 (856,626)
	824,919	478,100
Construction in progress	 72,744	 302,987
Property and equipment, net	\$ 897,663	\$ 781,087

Depreciation expense for the years ended June 30, 2021 and 2020 was \$93.1 million and \$78.9 million, respectively.

Children's National owns various buildings at the Children's National Research and Innovation Campus for which an environmental retirement obligation was recorded. The balances of such liabilities were \$1.3 million and \$1.2 million as of June 30, 2021 and 2020, respectively.

During the year ended June 30, 2020, Children's National retired \$7.0 million of fully depreciated long-lived assets determined to have no future value. During the year ended June 30, 2021, Children's National sold or disposed of long-lived assets with a net book value of \$0.3 million.

6. Contributions Receivable

Unconditional promises to give as of June 30 were as follows:

(in thousands)	2021			2020		
Less than one year One to five years More than five years	\$	33,044 28,693 8,445	\$	48,494 30,601 13,670		
		70,182		92,765		
Less: Discount Allowance for uncollectible contributions	,	(2,779) (1,032)		(3,822) (1,216)		
Contribution receivable, net	\$	66,371	\$	87,727		

Contributions receivable greater than one year in time are discounted using a rate of return that a market participant would expect to receive over the period at the date the pledge is received. The discount rate used is commensurate with the risk involved and ranges from 0.25% to 5.75% based on the date the pledge is made. Loss from uncollectible pledges was \$6.4 million and \$0.3 million for the years ended June 30, 2021 and 2020, respectively.

7. Investments and Assets Whose Use is Limited

The composition and fair values of investments and assets whose use is limited, as reported on the accompanying Consolidated Balance Sheets, at June 30 is as follows:

(in thousands)	2021			2020		
Limited by terms of debt agreements Cash and short term investments Total assets whose use is limited	\$	2,232	\$	664		
by terms of debt agreements	\$	2,232	\$	664		
Limited for professional liability claims Cash and short term investments Fixed income securities Equity securities	\$	591 20,340 16,779	\$	454 18,157 15,287		
Total funded professional liability	\$	37,710	\$	33,898		
Investments Cash and short term investments Fixed income securities Equity securities Equity method investments Real estate investments Alternative investments Total Investments	\$	51,413 390,061 605,814 6,284 6,125 4,427 1,064,124	\$	152,681 338,026 327,920 5,708 6,125 2,965		
Interest in Beneficial Trusts Beneficial interests held by 3rd party Perpetual trusts held by 3rd party Total interest and beneficial trusts	\$ 	1,145 8,617 9,762	\$ 	783 6,405 7,188		
	<u> </u>	-,	-	.,		

Investments included approximately \$332.7 million and \$259.1 million at June 30, 2021 and 2020, respectively, of funds which are restricted by donors for specific programs or for capital improvements.

Children's National Medical Center and Subsidiaries Notes to Consolidated Financial Statements

Years Ended June 30, 2021 and 2020

Investment returns consisted of the following:

(in thousands) June 30, 2021						
	Donor				Total	
\$	23,190	\$	9,599	\$	32,789	
	(9,680)		-		(9,680)	
	21,290		2,830		24,120	
	34,800		12,429		47,229	
	89,047		46,417	_	135,464	
\$	123,847	\$	58,846	\$	182,693	
		Jur	ne 30, 2020			
	Donor				Total	
\$	18.679	\$	5.201	\$	23,880	
•	•	,	-	,	(11,243)	
	66,453		28,890		95,343	
	73,889		34,091		107,980	
	(54,897)		(26,427)		(81,324)	
	\$ \$	(9,680) 21,290 34,800 89,047 \$ 123,847 Without Donor Resctrions \$ 18,679 (11,243) 66,453 73,889	Without Donor Resctrions \$ 23,190	Without Donor Resctrions With Donor Restrictions \$ 23,190 \$ 9,599 (9,680) - 21,290 2,830 34,800 12,429 89,047 46,417 \$ 123,847 \$ 58,846 \$ Une 30, 2020 Without Donor Resctrions With Donor Restrictions \$ 18,679 \$ 5,201 (11,243) - 66,453 28,890 73,889 34,091	Without Donor Resctrions With Donor Restrictions \$ 23,190 \$ 9,599 \$ (9,680) - 21,290 2,830 34,800 12,429 89,047 46,417 \$ 123,847 \$ 58,846 \$ \$ June 30, 2020 Without Donor Resctrions With Donor Restrictions \$ 18,679 \$ 5,201 \$ (11,243) - 66,453 28,890 73,889 34,091	

Realized gains and losses are calculated by comparing proceeds upon sale of an investment to its original cost, or its cost less any adjustment recorded for other-than-temporary loss on investments where applicable. The change in unrealized gains and losses on investments reflects the increase or decrease during the period in the difference between the fair value and the carrying amount of securities. Interest and dividend earnings (net of expenses), net realized gains and losses on investments and the net change in unrealized gains and losses on investments are considered investment income and are included and primarily recorded in nonoperating revenue and expenses, net on the Consolidated Statement of Operations.

In October of 2013, Children's National and Inova Health Care Services ("Inova") partnered in a joint venture to create Pediatric Specialists of Virginia ("PSV"). PSV is a Virginia limited liability company which provides high-quality pediatric specialty care to the children of Northern Virginia through clinical excellence, innovation, education, research, and family-centered care. Children's National has a 50% investment in PSV, and it is accounted for under the equity method. Inova owns the remaining 50% of PSV.

PSV is governed by an eight-member Management Committee of which Children's National has four members. Any action by the Management Committee must be approved by a majority of the members, provided that it includes an affirmative vote by both one Inova representative and one Children's National representative.

Children's National Medical Center and Subsidiaries

Notes to Consolidated Financial Statements

Years Ended June 30, 2021 and 2020

Children's National's investment in PSV was \$6.3 million and \$5.7 million as of June 30, 2021 and 2020, respectively. Children's National's contributed cash of \$10.3 million and \$12.9 million to PSV during the year ended June 30, 2021 and 2020, respectively. Children's National's share of losses from PSV as of June 30, 2021 and 2020 were \$9.7 million and \$11.2 million, respectively and are included within investment income in the Consolidated Statements of Operations.

The total assets, liabilities, and members' equity as of June 30, 2021 and 2020, and the total revenue, expenses and net loss for the years then ended for PSV are as follows:

(in thousands)	2021	2020		
Total assets	\$ 26,434	\$ 23,918		
Total liabilities	13,866	12,501		
Members' equity	12,568	11,417		
Total revenue	35,838	31,704		
Total expenses	 55,197	 53,619		
Net loss	\$ (19,359)	\$ (21,915)		

8. Liquidity and Availability

As of June 30, 2021, financial assets and liquidity resources available within one year for general expenditure, such as operating expenses, scheduled principal payments on debt, and capital construction costs not financed with debt, were as follows:

(in thousands)	2021	2020
Financial assets		
Cash and cash equivalents	\$ 120,683	\$ 93,566
Short term investments	21,207	96,038
Short term assets whose use is limited by terms of debt agreement	2,232	509
Accounts receivable for patient services, net	290,910	207,666
Settlements due from third-party payors	9,736	24,041
Current contributions receivable without donor restrictions, net	3,887	3,690
Grants receivable	11,879	 15,659
Total financial assets available within one year	460,534	 441,169
Liquidity resources:		
Bank line of credit	 100,000	 100,000
Total financial assets and liquidity resources		
available within one year	\$ 560,534	\$ 541,169

As part of the Children's National's liquidity management plan, cash in excess of daily requirements is invested in either money market funds, short-term investments or long-term investments. Investment decisions are made based on anticipated liquidity needs, such that financial assets are available as general expenditures, liabilities, and other obligations come due. To manage liquidity, Children's National maintains a \$100.0 million line of credit, as discussed in Note 10, *Debt*.

In addition, Children's National has board designated investments which are available for general expenditure upon Board approval. The amount of board designated investments was \$671.1 million and \$427.7 million as of June 30, 2021 and 2020, respectively.

Through its budgeting process, the CNMC Board authorizes access and release of board designated funds, transfer among CNMC and its affiliates, and transfers to operating accounts by taking action that approves the use of the funds. The CNMC Board also maintains banking and signature policies that authorize individual signers to transfer investment funds to the operating accounts. The CNMC Board may also rely upon the review and recommendations of its Finance and Investment Committee and the Board of its Affiliates.

9. Derivative Instruments

Children's National recognizes its derivative instruments as either assets or liabilities in the Consolidated Balance Sheets at fair value in accordance with relevant accounting guidance.

The Center entered into a swap agreement in conjunction with its Bank Qualified Revenue Bonds. Pursuant to the swap agreement, the Center, pays the counterparty a fixed interest rate equal to 3.83% per annum and receives interest at a variable rate of 80% of the one-month USD-LIBOR plus 1.25% per annum. The total notional amount of the swap agreement was \$4.2 million as of June 30, 2020. The swap matured in December 2020.

Classification of derivatives in Consolidated Balance Sheets		Fair Mar	ket Va	et Value		
(in thousands)	20	021		2020		
Derivatives not designated as hedging instruments						
Liability on interest rate swap	\$		\$	60		
Classification of derivatives gain/(loss) in		•	•	decognized in		
Consolidated Statements of Operations (in thousands)		021	iue Ov	zer Expense 2020		
Derivatives not designated as hedging instrument						
Unrealized gain on interest rate swap Realized gain/(loss) on interest rate swap	\$	60	\$	33 193		
Net realized and unrealized gain/(loss) on swap agreement	\$	60	\$	226		

10. Debt

As of June 30, long-term debt consisted of the following:

(in thousands)	2021	2020		
Series 2015 bonds maturity between July 15, 2019 and July 15, 2044, interest rates ranging from 4.00% to 5.00% Series 2020 bonds, interest only at 2.93%,	\$ 350,230	\$	357,735	
maturing on July 15, 2050	300,000		_	
Bank Qualified Revenue Bonds	7,775		8,375	
Loan payable to Bank of America	-		96,944	
Other long-term debt	57,963		-	
Notes payable	 18,820		18,820	
Total debt	734,788		481,874	
Unamortized premiums and discounts, net	24,317		26,737	
Unamortized debt issuance costs	(9,873)		(4,744)	
	749,232		503,867	
Less: Current portion	 (11,303)		(13,858)	
Total long-term debt	\$ 737,929	\$	490,009	

Series 2015 Bonds

In September 2015, the Children's National Obligated Group ("Obligated Group") borrowed from the District of Columbia (the "District") the proceeds of a series of tax-exempt revenue refunding bonds ("Series 2015 Bonds") issued by the District in the principal amount of \$374.0 million. The Obligated Group consists of Children's Hospital, CNWR (joined September 2016), and the Foundation. The Series 2015 Bonds were sold at a premium of \$39.8 million which is being amortized using the effective interest method. The amortization expense for the years ended June 30, 2021 and 2020 was \$2.4 million and \$2.6 million, respectively. The proceeds were used to advance refund the outstanding Series 2008 and Series 2005 Bonds and pay the cost of issuance associated with the Series 2015 Bonds. The Series 2005 Bonds and the Series 2008 Bonds (\$139.5 million and \$248.6 million outstanding as of the advance refunding date, respectively) were issued or refinanced as tax-exempt revenue bonds with fixed interest rates and a final maturity date of July 2035 and July 2044, respectively. The Series 2005 Bonds and the Series 2008 Bonds each had a call provision where the bonds could not be redeemed until July 2018. On July 15, 2018 the bonds were redeemed for \$394.2 million, including interest.

The Series 2015 Bonds are comprised of four tranches:

- \$195,030,000 5.00% Serial Bonds due July 15, 2016 through July 15, 2035
- \$40,315,000 4.00% Term Bonds due July 15, 2040
- \$50,000,000 5.00% Term Bonds due July 15, 2040
- \$88,615,000 5.00% Term Bonds due July 15, 2044

Children's National Medical Center and Subsidiaries Notes to Consolidated Financial Statements

Years Ended June 30, 2021 and 2020

Series 2020 Bonds

In August 2020, the Obligated Group issued the Children's Hospital Series 2020 Taxable Bonds ("Series 2020 Bonds") in the principal amount of \$300.0 million. The proceeds from the sale of the Series 2020 Bonds were used to finance general corporate purposes of the Obligated Group, refinance the Bank of America Loan and pay expenses in conjunction with the issuance of the Series 2020 Bonds. The Series 2020 Bonds bear interest at a fixed rate of 2.93 percent per annum and mature on July 15, 2050 with interest-only payments due January 15 and July 15 of each year. Children's National paid \$2.7 million of debt issuance costs for the Series 2020 Bonds during the year ended June 30, 2021.

The most restrictive covenant for the Series 2015 and 2020 Bonds requires the Obligated Group to maintain a minimum debt service coverage ratio of 1.2. The Obligated Group was in compliance with this covenant as of June 30, 2021.

Bank of America Loan

In March 2013, the Hospital entered into a loan agreement with Bank of America ("BoA") to borrow \$75.0 million. In June 2017, the loan agreement was amended and extended the maturity date of the loan to June 2020. Interest payments of LIBOR plus 44 basis points were due on the first of each month and the principal was to be due on the maturity date. The proceeds from the borrowing were to be used for general business purposes including increasing its cash reserve. In conjunction with the master borrowing agreement, BoA requires compliance with predetermined debt coverage ratios and a minimum cash balance.

In June 2019, the Hospital entered into an amended loan agreement with BoA for \$100.0 million and extended the maturity date of the loan to June 1, 2024. Interest is accrued at the LIBOR Daily Floating Rate plus 54 basis points. The amended agreement requires payments of principal and interest, which are due monthly beginning August 1, 2019. The additional \$25 million in borrowing was used to terminate Children's National's 2005 interest rate swap. The BoA loan was repaid in August 2020.

Bank Qualified Revenue Bonds

The HSC Pediatric Center is obligated under Bank Qualified Revenue Bonds, in the original principal amount of \$11,525,000, which were scheduled to mature (subject to prior redemption) on January 1, 2035. The bank had the option to terminate the loan and call the debt on December 17, 2020. Principal payments were made annually, and interest payments were made monthly. The variable interest rate on the bonds was the lesser of the bank rate as determined in accordance with the indenture and the maximum rate permitted by law. In April 2020, the loan was refinanced through the same bank for the amount outstanding at that date of \$8,475,000. The refinanced loan has a 15-year term with scheduled monthly principal payments of \$50,000 and interest payments. The variable interest rate is equal to 79% of the sum of the 1-month London Inter-bank Offer Rate ("LIBOR") plus 1.45%, as defined.

Notes Payable

On June 20, 2019, CITI NMTC SUBSIDIARY CDE XXXIV, LLC, a Delaware limited liability company, issued two loans to Building 52/53 Borrower providing historic and new market rehabilitation tax credit financing for two buildings and certain real property located at 7115 and 7125 13th Place, NW, Washington, D.C. known as Walter Reed Building 52 and Building 53.

The first loan, Promissory Note A1 in the amount of \$6,132,174, accrues interest at 1.0% per year and is computed on the basis of a 360-day year, based upon four 90-day quarters. The loan has a 30-year term with interest only payments required until June 2026. Payments are due quarterly on the 1st day of each March, June, September and December. Upon the conclusion of the interest only period payments in the amount of \$74,758, consisting of both interest and principal begin on September 1, 2026. The loan matures on June 20, 2049.

Children's National Medical Center and Subsidiaries

Notes to Consolidated Financial Statements Years Ended June 30, 2021 and 2020

The second loan, Promissory Note B1, in the amount of \$2,687,826, accrues interest at 1.0% per year and is computed on the basis of a 360-day year, based upon four 90-day quarters. The loan has a 30-year term with interest only payments required until June 2026. Payments are due quarterly on the 1st day of each March, June, September and December. Upon the conclusion of the interest only period payments in the amount of \$32,768, consisting of both interest and principal begin on September 1, 2026. The loan matures on June 20, 2049.

On June 20, 2019, NTCIC-CNWR, LLC, a Delaware limited liability company, issued two loans to Building 52/53 Borrower providing historic and new market rehabilitation tax credit financing for Walter Reed Building 52 and Building 53.

The first loan, Promissory Note A2 in the amount of \$7,363,526, accrues interest at 1.0% per year and is computed on the basis of a 360-day year, based upon four 90-day quarters. The loan has a 30-year term with interest only payments required until June 2026. Payments are due quarterly on the 1st day of each March, June, September and December. Upon the conclusion of the interest only period payments in the amount of \$89,770, consisting of both interest and principal begin on September 1, 2026. The loan matures on June 20, 2049.

The second loan, Promissory Note B2 in the amount of \$2,636,474, accrues interest at 1.0% per year and is computed on the basis of a 360-day year, based upon four 90-day quarters. The loan has a 30-year term with interest only payments required until June 2026. Payments are due quarterly on the 1st day of each March, June, September and December. Upon the conclusion of the interest only period payments in the amount of \$32,142, consisting of both interest and principal begin on September 1, 2026. The loan matures on June 20, 2049.

The notes are collateralized by Building 52/53 Borrower's property and the improvements. Building 52/53 Borrower may not encumber, transfer ownership, relocate or otherwise act so as to decrease the value of all, or any portion of, the property without prior written consent. The notes are guaranteed by Children's National.

Other Long-Term Debt

In September 2020, Children's Hospital was conveyed title to certain property and land located in Prince George's County, MD that it previously leased from a third-party developer under an operating lease. In exchange for deed and title to the property, Children's Hospital entered into a lease-leaseback transaction with an unrelated third party. Children's National guarantees the lease payments made by Children's Hospital. For accounting purposes, this transaction was accounted for as an in-substance net financing as a lease does not exist with the unrelated third party, that is, the right to control the use of the asset was not conveyed to the third party both during and after the leaseback transaction. Children's National recorded other long-term debt, net of debt issuance costs, in the amount of \$55.8 million, assets of \$54.5 million and removed the existing operating lease liability and right-of-use assets of \$30.2 million and \$28.3 million, respectively from its Consolidated Balance Sheet as of the transaction date. No gain or loss was recorded as a result of this transaction during the year ended June 30, 2021. The other-long term debt is amortized based on the monthly lease payments using the effective interest method at an interest rate of 3.14%.

Lines of Credit

On January 23, 2020, the Hospital entered into a \$50.0 million line of credit agreement with JP Morgan Chase Bank, N.A. The line of credit accrued interest at a variable rate equal to the 1 Month LIBOR plus 30 basis points and a commitment fee of 6 basis points. This agreement expired on January 30, 2021. On March 27, 2020, the Hospital entered into an additional \$50.0 million line of credit with JP Morgan Chase Bank, N.A. The line of credit accrued interest at a variable rate equal to the 1 Month LIBOR plus 30 basis points and a commitment fee of 10 basis points. This agreement expired on September 30, 2020.

On January 29, 2021, Children's Hospital entered into a \$100.0 million revolving Line of Credit with Capital One, N.A. for a one-year term (the Capital One credit agreement). The Capital One credit agreement bears interest at a variable rate equal to the 1 Month LIBOR plus 40 basis points and a commitment fee of 25 basis points. There were no amounts outstanding as of June 30, 2021.

Maturities and sinking fund requirements of long-term debt outstanding for the next 5 years and thereafter as of June 30, 2021 were as follows:

(in thousands)	
2022	\$ 9,036
2023	9,499
2024	10,046
2025	10,564
2026	11,099
Thereafter	 684,544
	\$ 734,788

Total interest expense was \$29.3 million and \$20.2 million for the years ended June 30, 2021 and 2020, respectively. Cash paid for interest was \$26.9 million and \$25.4 million for the years ended June 30, 2021 and 2020, respectively, and includes capitalized interest for construction projects of \$0.9 million and \$2.8 million, net of investment income for the year ended June 30, 2021 and 2020, respectively.

11. Endowments

Children's National endowment consists of individual donor restricted endowment funds for a variety of purposes. In addition, contributions receivables, split interest agreements, and other net assets have been designated for Children's National endowment.

The Board of Trustees of Children's National has interpreted the "Uniform Prudent Management of Institutional Funds Act" ("UPMIFA") as requiring the preservation of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, Children's National classifies net assets with donor restrictions (a time restriction in perpetuity), (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the donor-restricted endowment fund that is not classified as net assets with donor restrictions (a time restriction in perpetuity) is classified as net assets with donor restrictions (a purpose restriction) until those amounts are appropriated for expenditure by Children's National in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance with UPMIFA, Children's National considers the following factors in making a determination to appropriate or accumulate endowment funds:

Children's National Medical Center and Subsidiaries

Notes to Consolidated Financial Statements Years Ended June 30, 2021 and 2020

- (1) The duration and preservation of the fund;
- (2) The purposes of Children's National and the donor-restricted endowment fund;
- (3) General economic conditions;
- (4) The possible effect of inflation and deflation;
- (5) The expected total return from income and the appreciation of investments;
- (6) Other resources of Children's National; and
- (7) The investment policies of Children's National.

Endowment net asset composition by type of fund for the years ended June 30 were as follows:

(in thousands)	2021							
	Without I	Oonor	Wi	th Donor				
	Restrict	ions	Res	strictions		Total		
Donor-restricted endowment funds								
Historical gift value	\$	-	\$	164,725	\$	164,725		
Appreciation				98,304		98,304		
Total endowment funds	\$		\$	263,029	\$	263,029		
(in thousands)				2020				
	Without Restric		With Donor Restrictions			Total		
Donor-restricted endowment funds Historical gift value	\$	_	\$	157,602	\$	157,602		
Appreciation		_	·	47,280		47,280		
Total endowment funds	\$	-	\$	204,882	\$	204,882		

Changes in endowment net assets for the years ended June 30 were as follows:

(in thousands)	2021					
	Without Donor Restrictions			ith Donor strictions		Total
Endowment net assets, beginning of year	\$	-	\$	204,882	\$	204,882
Investment return, net		-		58,892		58,892
Redesignation of net assets		-		1,006		1,006
Gifts		-		7,097		7,097
Loss from unollectible pledges		-		(1,234)		(1,234)
Appropriation for expenditure				(7,614)		(7,614)
Endowment net assets, end of year	\$		\$	263,029	\$	263,029
				2020		
(in thousands)	14/11 4					
	Without			ith Donor		Total
	Restri	ctions	Ke	strictions		Total
Endowment net assets, beginning of year	\$	-	\$	196,137	\$	196,137
Investment return, net		-		7,707		7,707
Redesignation of net assets		-		(100)		(100)
Gifts		-		8,344		8,344
Appropriation for expenditure				(7,206)		(7,206)
Endowment net assets, end of year	\$		\$	204,882	\$	204,882

36

Description of the amounts classified as net assets with donor restrictions held in perpetuity (endowments only) as of June 30 is a follows:

(in thousands)		2020			
Patient care	\$	67,230	\$	61,327	
Health-related education		6,521		6,481	
Research		90,974		89,794	
	\$	164,725	\$	157,602	

Endowment Funds with Deficits

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the value of the initial and subsequent donor gift amounts (deficit). When donor endowment deficits exist, they are classified as a reduction of net assets with donor restrictions. There were no deficits in donor gift amounts as of June 30, 2021 and 2020.

Return Objectives and Risk Parameters

Children's National has adopted endowment investment and spending policies that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of endowment assets. Under this policy, the return objective for the endowment assets, measured over a full market cycle, shall be to maximize the return against a blended index, based on the endowment's target allocation applied to the appropriate individual benchmarks. Children's National expects its endowment funds over time, to provide an average rate of return of approximately 5% annually. Actual returns in any given year may vary from this amount.

Strategies Employed for Achieving Investment Objectives

To achieve its long-term rate of return objectives, Children's National relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized gains) and current yield (interest and dividends). Children's National targets a diversified asset allocation that places greater emphasis on equity-based investments to achieve its long-term objectives within prudent risk constraints.

Endowment Spending Allocation and Relationship of Spending Policy to Investment Objectives

The Board of Trustees of Children's National determines the method to be used to appropriate endowment funds for expenditure. Calculations were performed for individual endowment funds at a rate of 4.5% of the three-year rolling average using a monthly average over the most recent 36 months ended June 30th. The corresponding calculated spending allocations were distributed annually in the first month of the fiscal year from the current net total or accumulated net total investment returns for individual endowment funds. In establishing this policy, the Board considered the expected long-term rate of return on its endowment. Accordingly, over the long term, Children's National expects the current spending policy to allow its endowment to grow at between 3-8% annually, consistent with its intention to maintain the purchasing power of the endowment assets as well as to provide additional real growth through new gifts.

12. Net Assets with Donor Restrictions

Net assets with donor restrictions, consisting of cash, investments, and contributions receivable, were available for the following purposes at June 30:

(in thousands)		2020		
Patient care	\$	192,941	\$	143,659
Building expansion and equipment		3,303		3,774
Health-related education		9,248		7,595
Research		31,104		31,020
Endowment funds		164,725		157,602
Charitable remainder trusts		1,145		782
	\$	402,466	\$	344,432

13. Insurance

Children's National self-insures for malpractice and general liability claims up to a retention limit and carries excess coverage above that limit. On August 1, 1997, Children's National established the Captive as a wholly owned captive insurance company to assume the retained portion of medical malpractice, employment, and general liability claims of Children's National arising on or after August 1, 1997. Cash transfers to the Captive are based on premium levels established by the Captive's management, as well as Cayman Islands statutory capital requirements.

The reserve for claims shown in the accompanying Consolidated Balance Sheets represents the reserve for asserted and unasserted malpractice and comprehensive general liability claims against Children's National and its affiliated physicians. The reserve for claims is estimated by management using information supplied by legal counsel and an independent actuarial firm.

Malpractice and other claims in excess of the reserve for claims have been asserted against Children's National, and it is possible that actual claim liabilities could differ from estimated amounts in the near term. However, management and legal counsel do not believe that the ultimate cost of resolving asserted and unasserted claims related to events having occurred through June 30, 2021 are materially in excess of the reserve for claims and malpractice insurance coverage.

Children's National also self-insures for employee health and dental claims. In addition, Children's National has a deductible of \$500 thousand per occurrence for workers' compensation. Amounts accrued in the accompanying Consolidated Balance Sheets for the estimated cost of health and dental care claims incurred, including estimates for incurred but not reported amounts, were approximately \$7.6 million and \$5.7 million as of June 30, 2021 and 2020, respectively. Amounts accrued for workers compensation claims were approximately \$3.1 million and \$2.8 million as of June 30, 2021 and 2020, respectively.

14. Benefit Plans

Children's National sponsors defined contribution retirement plans that are available to substantially all employees. Children's National makes contributions to the plans on behalf of each participant based on the employee's level of contribution. The cost of the plan to Children's National was approximately \$29.0 million and \$27.6 million as of June 30, 2021 and 2020, respectively.

Children's National also has incentive compensation plans, based on achievement of organizational and individual goals, and deferred compensation arrangements. Assets and liabilities related to the deferred compensation arrangements are included in other noncurrent assets and other noncurrent liabilities in the accompanying Consolidated Balance Sheets in the amount of approximately \$44.9 million and \$35.1 million as of June 30, 2021 and 2020, respectively.

15. Leases

Children's National determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use assets, current portion of operating lease liabilities and operating lease liabilities on the Consolidated Balance Sheet. Financing leases are included in financing right-of-use asset, current portion of finance lease liabilities and finance lease liabilities on the Consolidated Balance Sheet. Leases are recognized based on the present value, net of the future minimum lease payments over the lease term using the organization's incremental borrowing rate based on the information available at commencement and include both lease and nonlease components. The ROU asset is derived from the lease liability and also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Certain lease agreements for real estate include payments based on actual common area maintenance expenses and others include rental payments adjusted periodically for inflation. These variable lease payments are recognized in other operating expenses, net, but are not included in the rightof-use asset or liability balances. Lease agreements may include one or more renewal options which are at the organization's sole discretion. Children's National does not consider the renewal options to be reasonably likely to be exercised, therefore they are not included in ROU assets and lease liabilities. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term for operating leases.

In accordance with ASC 842, *Leases*, Children's National has elected to not recognize ROU assets and lease liabilities for short-term leases with a lease term of 12 months or less. Children's National recognizes the lease payments associated with its short-term leases as an expense on a straight-line basis over the lease term. Variable lease payments associated with these leases are recognized and presented in the same manner as all other leases.

Children's National is obligated under various operating and financing real property and equipment leases for medical and administrative offices and equipment with remaining terms of 1 to 27 years, some of which include options to extend or options to terminate the leases. Several of these leases contain escalation clauses, with fixed-rate increases ranging from 2%-4%.

Lease expense for the years ended June 30 are as follows:

(in thousands)

	2021			2020
Financing lease expense:				
Amortization of right-of-use assets	\$	10,115	\$	9,911
Interest on lease liabilities		5,434		4,782
Opearting lease expense		15,800		20,618
Short-term lease expense		2,945		4,284
Variable lease expense		3,527		3,288
Total lease cost	\$	37,821	\$	42,883

Children's National Medical Center and Subsidiaries Notes to Consolidated Financial Statements

Years Ended June 30, 2021 and 2020

Commitments related to non-cancellable operating and financing for the years ending June 30 are as follows:

(in thousands)	Operating Leases			Financing Leases			
2022	\$	16,400	\$	14,074			
2023		13,401		14,463			
2024		13,348		14,745			
2025		12,282		15,145			
2026		11,969		15,507			
2027 and thereafter		61,292		124,182			
Total future minimum payments		128,692		198,116			
Less: Present Value Discount		(26,825)		(50,634)			
Present value of net minimum lease payments	\$	101,867	\$	147,482			

The weighted average remaining lease term and discount rate as of June 30, 2021 is as follows:

Weighted average remaining lease terms (in years):

Operating Leases Financing Leases	9.62 12.31
Weighted average discount rate:	
Operating Leases	4.27%
Financing Leases	3.81%

For the year ended June 30, supplemental cash flow information related to leases was as follows:

(in thousands)

Cash paid (received) for amounts included in the measurement of lease liabilities:

	2021	2020		
Operating cash flows for operating leases	\$ 15,247	\$ 15,351		
Operating cash flows for financing leases	3,977	2,942		
Financing cash flows for financing leases	5,787	7,220		
Right of assets obtained in exchange for lease liablities				
Operating leases	\$ 1,286	\$ 32,424		
Financing leases	1,418	104,347		

16. Concentrations of Credit Risk

Financial instruments which subject Children's National to concentrations of credit risk consist primarily of cash and cash equivalents, investments, assets who use is limited and patient accounts receivable.

Children's National grants credit without collateral to its patients, most of whom are local residents insured under third-party payor agreements. The mix of accounts receivable, net was as follows:

	2021	2020
Managed Care/Commercial	45 %	50 %
Maryland Medicaid	25	24
District of Columbia Medicaid	12	8
Virginia Medicaid and other	16	17
Self-pay	2	1
	100 %	100 %

17. Functional Expenses

Children's National provides health care services to children both within and outside its geographical service area. Children's National's consolidated financial statements report certain expense categories that are attributable to more than one health care service or support function. Therefore, these expenses require an allocation on a reasonable basis that is consistently applied. Costs not directly attributable to a function, including depreciation, amortization, interest and other occupancy costs, are allocated to a function based on a square footage or units of service basis. Expenses related to providing these services are as follows:

(in thousands)	June 30, 2021									
		Support	Serv	rices		Program	Serv	/ices		
				nagement						
Operating expenses:	Fur	ndraising	and	d General	Pa	atient Care	R	esearch		Total
Salaries, wages and benefits	\$	5,398	\$	196,104	\$	655,907	\$	54,859	\$	912,268
Supplies & other		1,380		152,398		218,521		33,982		406,281
Medical claims expense		-		-		83,853		-		83,853
Depreciation & amortization		14		41,962		39,438		11,670		93,084
Insurance		-		10,379		6,592		-		16,971
Interest		-		8,417		20,727		166		29,310
Development expense		21,536		1,391		-		-		22,927
Total operating expenses	\$	28,328	\$	410,651	\$	1,025,038	\$	100,677	\$	1,564,694

(in thousands)	June 30, 2020									
		Support	Serv	/ices		Program	Serv	rices		
			Ma	nagement						
Operating expenses:	Fun	draising	an	d General	Pa	tient Care	R	esearch		Total
Salaries, wages and benefits	\$	4,896	\$	185,729	\$	643,972	\$	55,561	\$	890,158
Supplies & other		3,769		173,066		198,176		20,061		395,072
Medical claims expense		-		-		90,496		-		90,496
Depreciation & amortization		-		29,982		38,943		-		68,925
Insurance		32		9,191		11,281		9,954		30,458
Interest		-		5,655		13,786		-		19,441
Development expense		20,530		5,656		-		540		26,726
Total operating expenses	\$	29,227	\$	409,279	\$	996,654	\$	86,116	\$	1,521,276

18. Noncontrolling Interests

The following table reconciles the carrying amounts of Children's National's controlling interest and the noncontrolling interests for net assets without donor restrictions:

(in thousands)	Total	(Controlling Interest	ncontrolling Interests
Balance at June 30, 2019	\$ 755,826	\$	748,234	\$ 7,592
Excess of revenues over expenses Released from restrictions for property and equipment Other changes in net assets without donor restrictions	 120,877 1,018 (270)		120,877 1,018 (270)	 - - -
Balance at June 30, 2020	\$ 877,451	\$	869,859	\$ 7,592
Excess of revenues over expenses Released from restrictions for property and equipment Other changes in net assets without donor restrictions	111,033 2,519 (310)		111,259 2,519 (310)	 (226)
Balance at June 30, 2021	\$ 990,693	\$	983,327	\$ 7,366

19. Commitments and Contingencies

Children's National is involved in litigation and regulatory investigations arising in the ordinary course of business. After consulting with legal counsel, management estimates that these matters will be resolved without material adverse effect on Children's National's future financial position or results from operations.

20. Subsequent Events

Subsequent events have been evaluated by management through October 8, 2021 which is the date the consolidated financial statements were issued. There were no events that require adjustment to the consolidated financial statements or disclosure in the notes to the consolidated financial statements.





Report of Independent Auditors

To Board of Trustees of Children's National Medical Center

Kricewathhorsecroper up

We have audited the consolidated financial statements of Children's National Medical Center its subsidiaries as of and for the year ended June 30, 2021 and our report thereon appears on pages 1-2 of this document. That audit was conducted for the purpose of forming an opinion on the consolidated financial statements taken as a whole. The consolidating information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The consolidating information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the consolidating information is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole. The consolidating information is presented for purposes of additional analysis of the consolidated financial statements rather than to present the financial position, results of operations, changes in net assets and cash flows of the individual companies and is not a required part of the consolidated financial statements. Accordingly, we do not express an opinion on the financial position, results of operations, changes in net assets and cash flows of the individual companies.

October 8, 2021

Children's National Medical Center and Subsidiaries Supplementary Consolidating Balance Sheet June 30, 2021

			Obligated group)												
(in thousands)	Hospital	CNWR	Foundation	Eliminations	Obligated Group Total	CRI	s	Safekids	CP&A	css	PHN/CNHN	HSC	Other	Captive	Eliminations	Consolidated Total
Assets																
Current assets																
	\$ 56,790	s -	\$ 1.734	s -	\$ 58,524	\$	120 \$	-	\$ (597) \$ (7)	\$ -	\$ 59.992	\$ 954	\$ 1,697	\$ -	\$ 120,683
Short term investments	21,207	· _	· · · · · -		21,207		_	-		,	· -	-	· -	-		21,207
Short term assets whose use is limited by terms of debt ag		_	_		1,927			-		_	_	305	_		_	2,232
Accounts receivable, net	289,889	-	-	-	289,889		-	-	1,314	-	-	5,463	-	-	(5,756)	290,910
Settlements due from third-party payors	8,607	-	-	-	8,607		-	-		-	-	1,129	-	-		9,736
Contributions receivable, net		-	32,347	-	32,347		-	211	-	-	-		-	-	-	32,558
Grant receivable	1,884	-	-	-	1,884	6,	557	102	-	3,336	-	-	-	-	-	11,879
Inventories of supplies	14,636	-	-	-	14,636		-	-	661	-	-	75	-	-	-	15,372
Prepaid expenses and other	70,717				70,717		1	75	105		993	2,117	1,513	318	(32,627)	44,512
Total current assets	465,657		34,081		499,738		378	388	1,483	4,629	993	69,081	2,467	2,015	(38,383)	549,089
Property and equipment, net	588,305	100,824	120	-	689,249	7,2	282	738	2,830	-	-	32,432	170,942	-	(5,810)	897,663
Right of use assets, financing	112,754	-	-	-	112,754		-	-	655	-	-	106	-	-	-	113,515
Right of use assets, operating	75,039	-	-	-	75,039		-	2,985	4,479	-	-	6,721	-	-	-	89,224
Assets whose use is limited by professional liability claims	592	-	-	-	592		-	-	-	-	-	-	-	37,118	-	37,710
Investments	958,388	-	678,287	(726,154)	910,521	41,3	351	2,748	-	-	-	101,261	-	28,388	(41,352)	1,042,917
Contributions receivable, net	-	-	33,813	-	33,813		-	-	-	-	-	-	-	-		33,813
Loan receivable	94,225	-		-	94,225		-	-	-	-	-	-	-	-	(80,729)	13,496
Interest in beneficial trusts		-	9,762		9,762		-	-	-	-	-	-	-	-		9,762
Due from affiliates	515,718	-	12,645	(74,559)	453,804		-	-		-	-	-	-	-	(453,804)	-
Other	59,536		. ——		59,536		<u> </u>		1,351				285_		(14,550)	46,622
Total noncurrent assets	2,404,557	100,824	734,627	(800,713)	2,439,295	48,6		6,471	9,315			140,520	171,227_	65,506	(596,245)	2,284,722
Total assets	\$ 2,870,214	\$ 100,824	\$ 768,708	\$ (800,713)	\$ 2,939,033	\$ 55,3	311 \$	6,859	\$ 10,798	\$ 4,629	\$ 993	\$ 209,601	\$ 173,694	\$ 67,521	\$ (634,628)	\$ 2,833,811
Liabilities and Net Assets																
Current liabilities																
	\$ 41,746	\$ 3,050	\$ -	\$ -	\$ 44,796		414 \$	-	\$ 301	\$ 66	*	\$ 1,890	\$ 14,340	\$ 1,058		
Accrued salaries and other expenses	189,177	8	710	-	189,895	2,	713	173	2,603	2,266	126	3,589	2,506	-	(2,506)	201,365
Current portion of reserve for claims	27,208	-	-	-	27,208		-	-	-	-	-		-	22,817	(22,817)	27,208
Settlements due to third-party payors	1,689			-	1,689		-		-	-	-	3,339	-			5,028
Deferred revenue	3,688	1,114	196	-	4,998	9,6	514	(4)	-	-	-		-	482	(250)	14,840
Medical claims payable		-	-	-			-	-	-	-	-	20,700	-	-	-	20,700
Current portion of long-term debt	10,703	-	-	-	10,703		-	-	-	-	-	600	-	-	-	11,303
Current portion of financing lease liabilities	7,761	-	374	-	7,761 5.624		-	- 591	160	-	-	25	-	-	-	7,946
Current portion of operating lease liabilities	5,250	<u>-</u>					158		1,344			-			- 	7,717
Total current liabilities	287,222	4,172	1,280		292,674	12,8	399	760	4,408	2,332	126	30,143	16,846	24,357	(38,632)	345,913
Noncurrent liabilities																
Long-term debt	712,487	-	-	-	712,487		-	-	-	-	-	7,080	18,362	-	-	737,929
Long-term financing lease liabilities	138,535	-		-	138,535		-		919	-	-	82	-	-	-	139,536
Long-term operating lease liabilities	78,788	-	(374)	-	78,414	(-	158)	3,824	4,306	-	-	7,764	-			94,150
Reserve for claims	77,128		-		77,128							1,143		14,301	(14,301)	78,271
Due to affiliates	-	74,559	-	(74,559)	-	362,6	511	418	27,640	2,925	3,622	56,587	1	-	(453,804)	-
Interest rate swaps	40,648	1,267	296	-	42,211		-	-	1,351	-	-	1,291	- 00 700	-	(00.700)	44,853
Other long-term liabilities							 						80,729		(80,729)	
Total noncurrent liabilities	1,047,586	75,826	(78)	(74,559)	1,048,775	362,4		4,242	34,216	2,925	3,622	73,947	99,092	14,301	(548,834)	1,094,739
Total liabilities	1,334,808	79,998	1,202	(74,559)	1,341,449	375,	302	5,002	38,624	5,257	3,748	104,090	115,938	38,658	(587,466)	1,440,652
Net assets (deficit)																
Without donor restrictions - controlling interest	1,177,475	20,826	368,223	(368,223)	1,198,301	(361,	392)	(1,103)	(27,826) (628)	(2,755)	105,288	50,390	28,863	(5,811)	983,327
Without donor restrictions - noncontrolling interest	-	-	-		-		-	-	-	-	-	-	7,366	-	-	7,366
With donor restrictions	357,931		399,283	(357,931)	399,283	41,3		2,960				223			(41,351)	402,466
Total net assets (deficit)	1,535,406	20,826	767,506	(726,154)	1,597,584	(320,0	041)	1,857	(27,826	(628)	(2,755)	105,511	57,756	28,863	(47,162)	1,393,159
Total liabilities and net assets (deficit)	\$ 2,870,214	\$ 100,824	\$ 768,708	\$ (800,713)	\$ 2,939,033	\$ 55,3	311 \$	6,859	\$ 10,798	\$ 4,629	\$ 993	\$ 209,601	\$ 173,694	\$ 67,521	\$ (634,628)	\$ 2,833,811

Children's National Medical Center and Subsidiaries Supplementary Consolidating Statement of Operations Year Ended June 30, 2021

			Obligated Group	•											
					Obligated										
(in thousands)	Hospital	CNWR	Foundation	Eliminations	Group Total	CRI	Safekids	CP&A	CSS	PHN/CNHN	HSC	Other	Captive	Eliminations	Total
Operating revenue and other support															
Net patient service revenue	\$ 1,112,055	\$ -	\$ -	\$ -	\$ 1,112,055	\$ -	\$ (17)	\$ 27,498	\$ -	\$ -	\$ 20,384	\$ -	\$ -	\$ (32,840)	\$ 1,127,080
Capitation revenue	-	-	-	-	-	-	-	-	-	-	176,260	-	-	-	176,260
Grant revenue	11,113	-	-	-	11,113	57,468	225	779	20,077	-	-	-	-	-	89,662
Other operating revenue	145,794	85	274	(3,940)	142,213	415	1,312	866	-	1,721	1,178	2,441	10,904	(60,404)	100,646
Contributions	1,017	-	23,483	-	24,500	-	1,002	-	-	-	26	-	-	-	25,528
Net assets released from restrictions used for operations	17,583		1,880		19,463	8,218	3,684				33				31,398
Total operating revenue and other support	1,287,562	85	25,637	(3,940)	1,309,344	66,101	6,206	29,143	20,077	1,721	197,881	2,441	10,904	(93,244)	1,550,574
Expenses															
Salaries, wages, and benefits	768,219	306	-	-	768,525	53,269	2,702	18,334	16,856	1,717	50,865	-	-	-	912,268
Supplies and other	347,513	4,624	-	(3,940)	348,197	43,611	3,385	12,513	2,791	1,453	36,286	141	1,595	(43,691)	406,281
Medical claims expense	-	-	-		-	-	-	-	-	-	116,693	-	-	(32,840)	83,853
Depreciation and amortization	83,703	1,240	-	-	84,943	2,290	119	450	-	-	3,469	1,813	-	-	93,084
Provision for insurance	17,228	-	-	-	17,228	60	-	214	33	-	24	-	10,316	(10,904)	16,971
Interest and amortization	26,880	59	-	-	26,939	-	-	43	-	-	254	2,074	-	-	29,310
Development expense			22,927		22,927						-				22,927
Total expenses	1,243,543	6,229	22,927	(3,940)	1,268,759	99,230	6,206	31,554	19,680	3,170	207,591	4,028	11,911	(87,435)	1,564,694
Operating income (loss)	44,019	(6,144)	2,710		40,585	(33,129)		(2,411)	397	(1,449)	(9,710)	(1,587)	(1,007)	(5,809)	(14,120)
Non-operating revenues and expenses															
Investment return, net	20,114	-	73,177	-	93,291	-	-	-	-	-	16,498	-	14,058	-	123,847
Realized and change in unrealized fair															
value of interest rate swaps	-	-	-	-	-	-	-	-	-	-	60	-	-	-	60
Inherent contribution from acquisition of HSC	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other non-operating loss, net	241				241						1,005				1,246
Total non-operating revenues and expenses	20,355		73,177		93,532						17,563		14,058		125,153
Excess (deficiency) of revenues over expenses	\$ 64,374	\$ (6,144)	\$ 75,887	\$ -	\$ 134,117	\$ (33,129)	\$ -	\$ (2,411)	\$ 397	\$ (1,449)	\$ 7,853	\$ (1,587)	\$ 13,051	\$ (5,809)	\$ 111,033

Children's National Medical Center and Subsidiaries Supplementary Consolidating Balance Sheet – The HSC Foundation and Subsidiaries Year Ended June 30, 2021

(in thousands)	he HSC undation	Р	he HSC ediatric Center	alth Services for Children with ecial Needs, Inc.	6C Home are, LLC	2013 Holdings, l	nc.	 Total
Assets								
Current assets								
Cash and cash equivalents	\$ 10,305	\$	(4)	\$ 49,691	\$ -	\$	-	\$ 59,992
Short term assets whose use is limited by terms of debt agreement	-		-	305	-		-	305
Accounts receivable, net	-		3,943	-	1,520		-	5,463
Settlements due from third-party payors	-		1,129	-	-		-	1,129
Inventories of supplies	401		75 532	1 151	33		-	75 2,117
Prepaid expenses and other	 			 1,151			<u> </u>	
Total current assets	 10,706		5,675	 51,147	 1,553		<u> </u>	 69,081
Property and equipment, net	371		28,308	3,742	11		-	32,432
Right of use assets, financing			0.007	106	440			106
Right of use assets, operating	- E4 E02		2,827	3,448	446		-	6,721
Investments	 54,583		47	 46,631	 		<u> </u>	 101,261
Total noncurrent assets	 54,954		31,182	 53,927	 457			 140,520
Total assets	\$ 65,660	\$	36,857	\$ 105,074	\$ 2,010	\$	-	\$ 209,601
Liabilities and Net Assets								
Current liabilities								
Accounts payable	\$ 3	\$	383	\$ 1,494	\$ 10	\$	-	\$ 1,890
Accrued salaries and other expenses	(21)		800	2,611	199		-	3,589
Settlements due to third-party payors	-		3,847	(508)	-		-	3,339
Medical claims payable	-		-	20,700	-		-	20,700
Current portion of long-term debt	=		600	-	-		-	600
Current Portion of Finance Lease Liabilities	 			 25	 			 25
Total current liabilities	 (18)		5,630	 24,322	 209			 30,143
Noncurrent liabilities								
Long-term debt	-		7,080	=	-			7,080
Long-term Finance Lease Liabilities				82				82
Long-term operating lease liabilities	-		3,338	3,966	460		-	7,764
Reserve for claims	-		1,029	91	23		-	1,143
Due to affiliates	(15,448)		36,768	44,458	(9,191)		-	56,587
Interest rate swaps	- 1,291		-	-	-		-	1 201
Other long-term liabilities	 			 	 (0.700)		-	 1,291
Total noncurrent liabilities	 (14,157)		48,215	 48,597	 (8,708)		<u> </u>	 73,947
Total liabilities	 (14,175)		53,845	 72,919	 (8,499)		_	 104,090
Net assets (deficit)								
Without donor restrictions - controlling interest	79,835		(17,210)	32,154	10,509		-	105,288
With donor restrictions	 		223	 	 			 223
Total net assets (deficit)	 79,835		(16,987)	 32,154	 10,509		_	 105,511
Total liabilities and net assets (deficit)	\$ 65,660	\$	36,857	\$ 105,074	\$ 2,010	\$		\$ 209,601

Children's National Medical Center and Subsidiaries Supplementary Consolidating Statement of Operations – The HSC Foundation and Subsidiaries Year Ended June 30, 2021

(in thousands)	 e HSC	P	he HSC ediatric Center	Health Services for Children with Special Needs, Inc.	HSC Home Care, LLC	2013 Holdings, Inc.	HSC Eliminations	Total
Operating revenue and other support								
Net patient service revenue	\$ _	\$	25,751	\$ -	\$ 9,679	\$ -	\$ (15,046)	\$ 20,384
Capitation revenue	_		· -	176,260	· -	-	-	176,260
Other operating revenue	_		676	76	426	-	-	1,178
Total Unrestricted Contributions	-		26	-	-	-	-	26
Net assets released from restrictions used for operations	 -		33					33
Total operating revenue and other support	-		26,486	176,336	10,105	-	(15,046)	197,881
Expenses								
Salaries, wages, and benefits	724		22,191	20,596	7,354	-	-	50,865
Supplies and other	595		15,259	17,942	2,490	-	-	36,286
Medical claims expense	_			131,739	-	-	(15,046)	116,693
Depreciation and amortization	425		1,506	1,531	7	-	· -	3,469
Provision for insurance	-		6	14	4	-	-	24
Interest and amortization	 71		180	3				254
Total expenses	 1,815		39,142	171,825	9,855		(15,046)	207,591
Operating income (loss)	 (1,815)		(12,656)	4,511	250			(9,710)
Non-operating revenues and expenses								
Investment return, net	11,507		10	4,981	-	-	-	16,498
Realized and change in unrealized fair							-	
value of interest rate swaps	-		60	-	-	-	-	60
Inherent contribution from acquisition of HSC	-		605	400	-	-	-	1,005
Other non-operating loss, net	 							
Total non-operating revenues and expenses	11,507		675	5,381				17,563
Excess (deficiency) of								
revenues over expenses	\$ 9,692	\$	(11,981)	\$ 9,892	\$ 250	\$ -	\$ -	\$ 7,853

Children's National Medical Center and Subsidiaries Notes to Consolidating Supplementary Information Year Ended June 30, 2021

1. Basis of Presentation—Consolidating Supplementary Information

The consolidating supplementary information ("consolidating information") presented on pages 45-48 was derived from and relates to the underlying accounting and other records used to prepare the consolidated financial statements. The consolidating information is presented for purposes of additional analysis of the consolidated financial statements, rather than to present the financial position and results of operations, changes in net assets and cash flows of the individual companies within Children's National and is not a required part of the consolidated financial statements. The individual companies within Children's National as presented within the consolidating information are disclosed within Note 1 to the consolidated financial statements.

Schedule of Expenditures of Federal Awards and Notes to Schedule of Expenditures of Federal Awards

	Assistance)					Passed to
Federal Program	Listing Number	Direct	Pass-Through	n Pass-Through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Sub- Recipients
rederal Frogram	Number	Direct	Pass-Illiougi	rass-IIII Ough Entity	Pass-Illiough Entity Sponsor Number	Experiultures	Recipients
Research and Development Cluster							
DEPARTMENT OF DEFENSE							
Department of the Army							
Military Medical Research and Development	12.420	\$ 1,158,392	\$ -			\$ 1,158,392	\$ 33,106
Military Medical Research and Development	12.420	-		University of Alabama-Birmingham	000516840-SC005-T001	6,518	3,652
Military Medical Research and Development	12.420	-		George Washington University	21-M10	2,017	-
Military Medical Research and Development	12.420	-		Binghamton University	020SUB00000095	25,424	-
Military Medical Research and Development	12.420	-		Sarcoma Alliance for Resrch through Collaboration	SARC-20191008	27,635	-
Military Medical Research and Development	12.420	-	3,613	Medstar Health Research Institute	5002028409	3,613	-
Military Medical Research and Development	12.420	-	101,008	Children's Hospital of Philadelphia	3211260622/PO# 20228798	101,008	-
Basic Scientific Research	12.431	24,528		_		24,528	
		1,182,920	166,215	_		1,349,135	36,758
NATIONAL SCIENCE FOUNDATION							
National Science Foundation							
Computer and Information Science and Engineering	47.070	38,607	_			38,607	_
Computer and Information Science and Engineering	47.070	-	63 283	The Research Foundation for SUNY	86479/2/1157719	63,283	_
Biological Sciences	47.074	63.469				63,469	_
Biological colorides	41.014	102,076	63,283	- -		165,359	
DEDARTMENT OF USALTHAND HUMAN OFFICE							
DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Community Living							
ACL National Institute on Disability, Independent Living, and							
Rehabilitation Research	93.433		170 560	Catholic University of America	407261 Sub 2 A2	179,560	
1 Chabitation 1 Cocaron	93.433		179,560		407201 3ub 2 A2	179,560	
			179,360	-		179,300	
Centers for Disease Control and Prevention							
Innovations in Applied Public Health Research	93.061	-	117,588	Creare LLC	S676 /PO 108128	117,588	-
Injury Prevention and Control Research and State and							
Community Based Programs	93.136	-		Emory University	Emorysub-20180318	59,376	-
Disabilities Prevention	93.184	-	1,994	MedStar Health Research Institute	5002027613	1,994	-
Preventive Health and Health Services Block Grant funded							
solely with Prevention and Public Health Funds	93.758			DC Department of Health	PO632928	93,812	
			272,770	_		272,770	
Food and Drug Administration							
Food and Drug Administration_Research	93.103	1,041,220	_			1,041,220	562,519
Food and Drug Administration_Research	93.103		30,000	Children's Hospital of Philadelphia	Sub#3201480820-PO20129997	30,000	-
Food and Drug Administration Research	93.103	_		Vanderbilt University	VUMC76676	19,582	_
Food and Drug Administration_Research	93.103	_		Institute for Advanced Clinical Trials	CNMC-01	88,313	_
1 ood and Drug Administration_Nesearch	93.103	1,041,220	137,895		CIVIVIC-01	1,179,115	562,519
		1,041,220	137,693	-		1,179,113	302,319
Health Resources and Services Administration							
Maternal Child Health Federal Consolidated Programs	93.110	-	56,414	Children's Hospital of Philadelphia	3209610521/PO# 20189289 - 3209610522/PO# 20274254	56,414	-
Emergency Medical Services for Children Access Program	93.127	108,167	-			108,167	-
		108,167	56,414	- -		164,581	
National Institutes of Health							
Environmental Health	93.113	914	_			914	-
Oral Diseases and Disorders Research	93.121	-	16,370	University of Colorado Denver	FY21.1047.001	16,370	-
Human Genone Project	93.172	594,404	-	•		594,404	-
Research Related to Deafness and Communication Disorders	93.173	-	47,467	Georgetown University	CRIAWD-7773445	47,467	-
Research and Training in Complementary and Integrative Health	93.213	-	64,315	Colorado State University	G-45171-02	64,315	-
Research on Healthcare Costs, Quality and Outcomes	93.226	95,976	-			95,976	-
Research on Healthcare Costs, Quality and Outcomes	93.226	-		Drexel University	AWD101148 (SUB00000286)	259	-
Research on Healthcare Costs, Quality and Outcomes	93.226	-	17,129		Sub#311812-PO803651	17,129	-
Research on Healthcare Costs, Quality and Outcomes	93.226	-	50,670	University of Michigan	3004658566	50,670	-
Mental Health Research Grants	93.242	758,790	-			758,790	105,433
Mental Health Research Grants	93.242	-		Georgetown University	AWD7772276-GR205181	170,242	-
Mental Health Research Grants	93.242	-		University of Virginia	GB10691.PO#2133159	242,744	-
Mental Health Research Grants	93.242	-		Creare LLC	Creare20181109	17,443	-
Mental Health Research Grants	93.242	-		George Washington University	20-M84	15,805	-
Mental Health Research Grants	93.242	-		George Washington University	20-S04R 82704 70270202	35,850	-
Mental Health Research Grants Mental Health Research Grants	93.242 93.RD	57,074	246,210	University of Maryland, College Park	82724-Z0279202	246,210 57,074	-
Alcohol Research Programs	93.RD 93.273	939,301	-			939,301	
, account together	55.215	333,301	-			303,001	-

Pederal Programs		Assistance						Passed to
Description of August Description Horsester Programs 19,277 19,200		Listing						Sub-
Dig Dig	Federal Program	Number	Direct	Pass-Through	n Pass-Through Entity	Pass-Through Entity Sponsor Number	Expenditures	Recipients
Dig Dig	Drug Abuse and Addiction Research Programs	93.279	529.208	_			529.208	51.937
Decompt of Applicat Research for Technological Immostration 10,740 1,740				92,182	Johns Hopkins University	2003164315		-
Denominy of Applied Research for Technological Procession (1) 1,535 1,53	Discovery and Applied Research for Technological Innovations	93.286	699,057	-			699,057	332,822
Description and Agricular Discource Placement in Communication Incommunication (1998) 1.00 1.0	Discovery and Applied Research for Technological Innovations	93.286	-	80,747	University of Maryland, College Park	39478-Z0581001	80,747	-
Morety Manuary Manua	Discovery and Applied Research for Technological Innovations	93.286	-	1,433	Kitware, Inc.	K001848-00-S02	1,433	-
Minor Mino			-					-
Control Promoted Research Control Co			-					-
Administration for Administration Engineering Control (2007) Administration for Administration Control (2007) Administration (2007) Administra			-					-
Court Cour			- 407.000	20,128	University of California, San Francisco	12654sc		
Michael Center for Advancing Transsertion Selections 1,00 1				-				1,415,151
Microal Counter for Advancing Translational Sciences 0.3.00 Counter for Advancin			5,530	44 726	University of Dittelyurah	0055252 (120010 24)		-
Mestoral Center for Advancing Translations Sciences 3.3.00 1.5.00 1			-					-
National Center for Advancing Translational Sciences 1,450 15,354 1								
Montang Calender for Advancing Translational Sciences 93.05 93.0			_					_
Pleasanch Infrastructure Programs 93.561 530.145 72.125 Centry Creek - I. Baus Beller Cancer Monitoria 93.261 73.25 73			_					_
Act Carrier Marrier Massach Marrier Marrier			539.145	-				_
Naming Research 19.3 de 19.4 d	21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	661,297	_			661,297	374,786
Naming Research 10.361	21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	-	28,736	Mayo Clinic	CRI-260212-01/PO #6757442	28,736	-
National Research 93.581 9.3503 15.050	Nursing Research	93.361	136,429	-	•		136,429	12,559
Cancer Cancer and Chaptonis Research S. 3.93 S. 3.7.4.61 S. 3.7.4.61 Cancer Declarion and Chaptonis Research S. 3.94 S. 3.9.4.66 18.7.41 Children's Hespital of Philadelphia 18.4.066 18.7.41 Children's Hespital of Philadelphia 18.4.066 18.7.41 Children's Hespital of Philadelphia 18.4.066 18.7.41 Children's Hespital Philadelphia 18.4.066 18.4.01	Nursing Research	93.361	-	16,217	Children's Hospital of Philadelphia	3200480521 PO#962352-RSUB	16,217	-
Cancer Debection and Diagnosis Research 9.3.34 9.4.54 18/41 Children's Hospital of Philadelphia GRT-307/PCB 2018789 - GRT-307-(4522/PCB 20271390) 18/4131 1-14.14 1-14.1	Nursing Research	93.361	-	30,503	University of Tennesee	A19-0157-S001		-
Carnor Debeschen and Diagnosis Research 93.94 - 187.413 1.134 Cargor Carnor Debeschen and Diagnosis Research 93.344 - 1.341 Cargor Carnor Debeschen and Diagnosis Research 93.345				-				
Cancer Delection and Diagnosis Research 9.3.94 . 11.341 			834,586	-				201,952
Cannor Poleschon and Dilignoise Research (1992) St. Julis Children's Research Hospital 12134041-7897213 12134041-789721								-
Cancer Treatment Research 93.395 68.474 199.201 Cancer Treatment Research 93.395 c			-					-
Cancer Treatment Research 93.395 - 74.346 Univer Treasment Research 93.395 - 48.814 Univer Treasment Research 93.395 - 68.475 Univer Treasment Research 93.395 - 74.475 Univer Treasment Research			-	7,913	St. Jude Children's Research Hospital	112134040-7897213		
Carnor Treatment Research			658,474	74.040	Unit of Tours M.D. Anderson Consul Cat	2004202500		199,220
Cancer Treatment Research			-					-
Cancer Treatment Research			-					-
Cancer Teatment Research								
Cancer Treatment Research			_					_
Cancer Treatment Research			_					_
Cancer Treatment Research			-					_
Cancer Treatment Research			-					_
Cancer Treatment Research	Cancer Treatment Research	93.395	-	8,393	Children's Hospital of Philadelphia	FP00026529 SUB501_01	8,393	-
Cancer Treatmert Research	Cancer Treatment Research	93.395	-	18,744	Children's Hospital of Philadelphia	FP00026529_SUB519_01	18,744	-
Cancor Treatmert Research			-					-
Cancer Treatment Research			-					-
Cancer Treatment Research			-					-
Cancer Treatment Research 93.395 - 104.257 St. Jude Children's Research Hospital 110068210-7999159 104,257 5. Cancer Control 93.399 - 7.794 Children's Hospital of Philadelphia P.0202193941PQ20219370 7.04			-					-
Cancer Control 93.398 - 58.024 Ceorge Washington University 20-M108 58.024 - Cancer Control 93.399 - 7.018 Children's Hospital of Philadelphia P.020219384/P.020219370 794 - Cardiovascular Diseases Research 93.837 3.042,898 7.018			-					-
Cancer Control			-					-
Cardiovascular Diseases Research			-					-
Cardiovascular Diseases Research 93.837 3,042,898 60,546 Cardiovascular Diseases Research 93.837 - 19,799 New England Research Institute Exhibit F to NERI MCTA 19,799 - 10,343 19,799 - 10,343 New England Research Institute Exhibit F to NERI MCTA 10,343 - 10,343								_
Cardiovascular Diseases Research 93.837 - 19,799 New England Research Institute Exhibit 16 NERI MCTA 19,799 - 1,0343 - 1,0343 - 1,0343 New England Research Institute Exhibit 16 NERI MCTA 19,343 - 1,0343			3 042 898	7,010	Official Strospical of Finadelphia	1 0202 10004		60 546
Cardiovascular Diseases Research 93.837 - 10,343 New England Research Institute Exhibit F to NERI MCTA 10,343 - Cardiovascular Diseases Research 93.837 - 33,971 Children's Hospital of Philadelphia 3200670521-XX / PO# 20195515-RSUB - 3200670522-XX / PO# 20288240 33,971 - Cardiovascular Diseases Research 93.837 - 86,883 Auscullech, Inc. ATX-CRI-1294 2195515-RSUB - 3200670522-XX / PO# 20288240 33,971 - Cardiovascular Diseases Research 93.837 - 25,906 Etiometry Inc. R44H_L117340 25,906 - Cardiovascular Diseases Research 93.837 - 36,814 Emory A38196 Cardiovascular Diseases Research 93.837 - 7,407 Emory A35977-Cost Reimbursable 7,407 - Cardiovascular Diseases Research 93.837 - 7,407 Emory A35977-Cost Reimbursable 7,407 - Cardiovascular Diseases Research 93.838 637,011 - Cardiovascular Diseases Research 93.838 - 28,661 University of Arizona UA Agreement 328534 28,990 CRIDIO DISEASE RESEARCH 93.839 1,637,964 1,			-	19.799	New England Research Institute	DOIT20180101-PrePaid-NERI		-
Cardiovascular Diseases Research 93.837 - 33.971 Children's Hospital of Philadelphia 3200670521-XX /PO # 20195515-RSUB - 3200670522-XX / PO# 20288240 33.971 - Cardiovascular Diseases Research 93.837 - 25.906 Etometry Inc. R44H-L117340 25.906 - Cardiovascular Diseases Research 93.837 - 155.912 The University of Chicago AWD100549 (SUB0000024) 185.912 - Cardiovascular Diseases Research 93.837 - 155.912 The University of Chicago AWD100549 (SUB0000024) 185.912 - Cardiovascular Diseases Research 93.837 - 7.407 Emory A355977-Cost Reimbursable 7.407 - Lung Diseases Research 93.838 74.710 - The Vision of Covernment of Cover			-					_
Cardiovascular Diseases Research 93,837 - 25,906 Etiometry Inc. R44HL117340 25,906 - Cardiovascular Diseases Research 93,837 - 185,912 The University of Chicago AWD100549 (SUB00000224) 185,912 - Cardiovascular Diseases Research 93,837 - 36,814 Emory A35941496 36,814 - Cardiovascular Diseases Research 93,837 - 7,407 Emory A359977-Cost Reimbursable 7,407 - Cardiovascular Diseases Research 93,838 74,8710 - (79,900 748,710 748,710 748			-					-
Cardiovascular Diseases Research 93.837 - 185,912 The University of Chicago AWD100549 (SUB00000224) 185,912 - Cardiovascular Diseases Research 93.837 - 36,814 - Cardiovascular Diseases Research 93.837 - 7,407 Emory A355977-Cost Reimbursable 7,407 - Lung Diseases Research 93.838 748,710 - - 7,407 - COVID-19 Lung Diseases Research 93.838 637,011 - - 637,011 - Lung Diseases Research 93.838 - 287,661 University of Arizona UA Agreement 328534 287,661 - Lung Diseases Research 93.838 - 38,393 Indiana University 8499-CRI 38,393 - Blood Diseases and Resources Research 93.839 - 133,464 Univ. of North Carolina at Chapel Hill 5105020 133,464 - Blood Diseases and Resources Research 93.839 - 142,699 Medical College of Wisconsin MCW20181219 24,294 -	Cardiovascular Diseases Research	93.837	-	86,883	Auscultech, Inc.	ATX-CRI-1293	86,883	-
Cardiovascular Diseases Research 93.837 - 36.814 (acadiovascular Diseases Research A381496 A381496 - 36.814 (acadiovascular Diseases Research 39.837 (acadiovascular Diseases Research 39.838 (acadiovascular Diseases Research 43.55977-Cost Reimbursable 7.407 (acadiovascular Diseases Research 7.487 (acadiovascular Diseases Research 7.848 (acadiovascular Diseases Research 7.487 (acadiovascular Diseases Adams) 7.407 (acadiovascular Diseases Adams) 7.407 (acadiovascular Diseases Adams) 7.407 (acadiovascular Diseases Adams) 7.407 (ac	Cardiovascular Diseases Research	93.837	-	25,906	Etiometry Inc.	R44HL117340	25,906	-
Cardiovascular Diseases Research 93,837 - 7,407 Emory A355977-Cost Reimbursable 7,407 - - 7,407 -			-	185,912	The University of Chicago	AWD100549 (SUB00000224)		-
Lung Diseases Research 93.838 748,710 745,710 7,950 COVID-19 Lung Diseases Research 93.838 637,011 637,011 Lung Diseases Research 93.838 287,661 University of Arizona UA Agreement 328534 287,661 Lung Diseases Research 93.838 38,393 Indiana University 8499-CRI 38,393 Blood Diseases and Resources Research 93.839 1,637,964 1,637,964 Blood Diseases and Resources Research 93.839 133,464 Univ. of North Carolina at Chapel Hill 5105020 133,464 Blood Diseases and Resources Research 93.839 142,699 Medical College of Wisconsin MCW20181219 24,294 Blood Diseases and Resources Research 93.839 7,848 Fred Hutchinson Cancer Research Center PO 1043125 CF 7,848 - Blood Diseases and Resources Research 93.839 82,125 University of Minnesota PO 1043125 CF 7,848 - Blood Diseases and Re			-					-
COVID-19 Lung Diseases Research 93.838 637,011 - Lung Diseases Research 93.838 - 287,661 University of Arizona UA Agreement 328534 287,661 - Lung Diseases Research 93.838 - 38,393 Indicate University 8499-CRI 38,393 - Blood Diseases and Resources Research 93.839 1,637,964 - 16,024 Blood Diseases and Resources Research 93.839 - 133,464 Univ. of North Carolina at Chapel Hill 5105020 133,464 - Blood Diseases and Resources Research 93.839 - 142,694 Medical College of Wisconsin MCW20181219 24,294 - Blood Diseases and Resources Research 93.839 - 142,699 Medical College of Wisconsin MCW20191009 142,699 - Blood Diseases and Resources Research 93.839 - 7,848 Fred Hutchinson Cancer Research Center PO 1043125 CF 7,848 - Blood Diseases and Resources Research 93.839 - 82,125 University of Minnesota PO 7900000480			-	7,407	Emory	A355977-Cost Reimbursable		-
Lung Diseases Research 93.838 - 287,661 University of Arizona UA Agreement 328534 287,661 - Lung Diseases Research 93.838 - 38,393 Indiana University 8499-CRI 38,994 16,024 Blood Diseases and Resources Research 93.839 1,637,964 16,024 Blood Diseases and Resources Research 93.839 - 133,464 Univ. of North Carolina at Chapel Hill 5105020 133,464 - Blood Diseases and Resources Research 93.839 - 24,294 Medical College of Wisconsin MCW20181219 24,294 - Blood Diseases and Resources Research 93.839 - 142,699 Medical College of Wisconsin MCW20191009 4 -<				-			-, -	7,950
Lung Diseases Research 93.838 - 38,393 Indianal University 8499-CRI 38,393 - Blood Diseases and Resources Research 93.839 1,637,964 - - 133,464 Univ. of North Carolina at Chapel Hill 5105020 133,464 - - 133,464 -						114.4		-
Blood Diseases and Resources Research 93.839 1,637,964 - 133,464 Univ. of North Carolina at Chapel Hill 5105020 133,464 - 133,464 Univ. of North Carolina at Chapel Hill 5105020 133,464 - 133,464 Univ. of North Carolina at Chapel Hill 5105020 133,464 - 133,464 Univ. of North Carolina at Chapel Hill 5105020 133,464 - 133,464 Univ. of North Carolina at Chapel Hill 5105020 133,464 - 133,464 Univ. of North Carolina at Chapel Hill 5105020 133,464 - 133,464 Univ. of North Carolina at Chapel Hill 5105020 133,464 - 133,464 Univ. of North Carolina at Chapel Hill 5105020 133,464 - 133,464 Univ. of North Carolina at Chapel Hill 5105020 133,464 - 133,464 Univ. of North Carolina at Chapel Hill 5105020 133,464 - 133,464 Univ. of North Carolina at Chapel Hill 5105020 133,464 - 133,464 Univ. of North Carolina at Chapel Hill 5105020 133,464 - 133,464 Univ. of North Carolina at Chapel Hill 5105020 133,464 - 133,464 Univ. of North Carolina at Chapel Hill 5105020 Univ. of North Carolina at Chapel Hill Stock of			-					-
Blood Diseases and Resources Research 93.839 - 133,464 -			1 627 001	38,393	indiana University	0499-CKI		40.004
Blood Diseases and Resources Research 93.839 - 24,294 Medical College of Wisconsin MCW20181219 24,294 - <			1,037,964	100 404	Univ. of North Carolina at Chanal Hill	5105020		16,024
Blood Diseases and Resources Research 93.839 - 142,699 Medical College of Wisconsin MCW20191009 142,699 - - Blood Diseases and Resources Research 93.839 - 7,848 Fed Hutchinson Cancer Research Center P0 1043125 CF 7,848 - Blood Diseases and Resources Research 93.839 - 82,125 University of Minnesota P007988801 82,125 - Blood Diseases and Resources Research 93.839 - 93 Vanderbilt University VUMC91809 933 - Blood Diseases and Resources Research 93.839 - 31,429 Blood Diseases Portion (Portion Control Center Research Portion Center Research Portion (Portion Center Research Portion Center Research Portion (Portion Center Research Portion Center			-					-
Blood Diseases and Resources Research 93.839 - 7,848 Fred Hutchinson Cancer Research Center PO 1043125 CF 7,848 - Blood Diseases and Resources Research 93.839 - 82,125 University of Minnesota P007988901 82,125 - Blood Diseases and Resources Research 93.839 - 93.3 Vanderbilt University VUMC91809 93.3 - Blood Diseases and Resources Research 93.839 - 31,429 Baylor College of Medicine PO7000000480 31,429 -			-	24,294 142 600	Medical College of Wisconsin			
Blood Diseases and Resources Research 93.839 - 82,125 University of Minnesota P007988801 82,125 - Blood Diseases and Resources Research 93.839 - 93.3 Vanderbilt University VUMC91809 93.3 - Blood Diseases and Resources Research 93.839 - 31,429 Baylor College of Medicine PO 7000000480 31,429 -								-
Blood Diseases and Resources Research 93.839 - 933 Vanderbilt University VUMC91809 933 - Blood Diseases and Resources Research 93.839 - 31,429 Baylor College of Medicine PO 7000000480 31,429 -								
Blood Diseases and Resources Research 93.839 - 31,429 Baylor College of Medicine PO 7000000480 31,429 -			_					-
			-					-
			-					-

	Assistance						Passed to
Federal Program	Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Sub- Recipients
Federal Program	Number	Direct	Pass-Inrough	Pass-Inrough Entity	Pass-Inrough Entity Sponsor Number	Expenditures	Recipients
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	359,639	-			359,639	20,453
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	110,629	Baylor College of Medicine	2U54AR068069-06	110,629	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	-	1,990	Duke University	5103373	1,990	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.RD	52,468	-			52,468	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	1,305,380				1,305,380	209,347
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-		Johns Hopkins University	2004092761	22,427	-
Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847 93.847	-		Kitware, Inc. University of Virginia	K002739-00-S01 GB10730.PO#2238820	83,022 193,236	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-		University of Alabama-Birmingham	000526569-SP002-SC001	67,991	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847			Academic Pediatric Association	APA20190424	930	
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	_		Children's Hospital of Pittsburgh	AWD00000120 (132569-1)	83.591	_
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	_		CoapTech Inc.	R44DK123910-CNMC	12,565	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	_		George Washington University	20-M12R	66,881	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	247,778	Vanderbilt University	VUMC75773	247,778	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	18,059	Baylor College of Medicine	PO 7000001068	18,059	-
Extramural Research Programs in the Neurosciences							
and Neurological Disorders	93.853	3,635,685	-			3,635,685	242,337
Extramural Research Programs in the Neurosciences							
and Neurological Disorders	93.853	-	6,716	Wake Forest University	WFUHS112671	6,716	-
Extramural Research Programs in the Neurosciences							
and Neurological Disorders	93.853	-	7,584	University of California, San Francisco	11081sc	7,584	-
Extramural Research Programs in the Neurosciences	02.052		25.007	Destruction (Inc. consists)	450000050	25 007	
and Neurological Disorders Extramural Research Programs in the Neurosciences	93.853	-	35,807	Boston University	4500002650	35,807	-
and Neurological Disorders	93.853			University of Minnesota	P006124704		
Extramural Research Programs in the Neurosciences	93.003	-	-	Offiversity of Ivillilesota	F000124704	-	-
and Neurological Disorders	93.853	_	15.802	University of California, San Francisco	9672sc	15.802	_
Extramural Research Programs in the Neurosciences	30.000		10,002	onversity of Gamornia, Garri randisco	307230	10,002	
and Neurological Disorders	93.853	_	71.547	University of Washington	UWSC11001	71,547	_
Extramural Research Programs in the Neurosciences			,			,	
and Neurological Disorders	93.853	_	21,284	Children's Hospital of Philadelphia	3201870620/ PO#20205855	21,284	-
Extramural Research Programs in the Neurosciences							
and Neurological Disorders	93.853	-	25,979	Children's Hospital of Philadelphia	3202030620 / PO# 20208366	25,979	-
Allergy and Infectious Diseases Research	93.855	599,914	-			599,914	-
Allergy and Infectious Diseases Research	93.855	-		University of Wisconsin	000000645 - 0000000872	75,583	-
Allergy and Infectious Diseases Research	93.855	-		University of Wisconsin	Sub#000000794	586,989	-
Allergy and Infectious Diseases Research	93.855	-		George Washington University	19-M90R	35,483	-
Allergy and Infectious Diseases Research	93.855	-		George Washington University	20-M106	20,704	-
Allergy and Infectious Diseases Research	93.855	-		George Washington University	20-M115	1,428	-
Allergy and Infectious Diseases Research Allergy and Infectious Diseases Research	93.855 93.855	-		George Washington University George Washington University	20-M120 20-M58R - 20-M58	168,124 19.819	-
Allergy and Infectious Diseases Research	93.855	-		George Washington University	20-M75	177,592	-
Allergy and Infectious Diseases Research	93.855			George Washington University	GWU20200928	25,686	
COVID-19 Allergy and Infectious Diseases Research	93.855	_		Massachusetts General Hospital	121R01AI127507	382,667	_
Allergy and Infectious Diseases Research	93.855	_		Massachusetts General Hospital	232069	151,714	_
Allergy and Infectious Diseases Research	93.855	_		Baylor College of Medicine	700000731	97,254	_
Allergy and Infectious Diseases Research	93.855	_		Northwestern University	60046645 CRI	153,128	_
Allergy and Infectious Diseases Research	93.855	-	144,710	Michigan State University	RC106925E	144,710	_
Allergy and Infectious Diseases Research	93.855	-	176,812	Weill Cornell Medical College	204403	176,812	-
Allergy and Infectious Diseases Research	93.855	-	267,435	Weill Cornell Medical College	203538	267,435	-
Allergy and Infectious Diseases Research	93.855	-		District of Columbia Center for AIDS Research	M0035RPTA380831IXXS	785	-
Allergy and Infectious Diseases Research	93.855		46,308	President and Fellows of Harvard College	117273-5115223	46,308	-
Allergy and Infectious Diseases Research	93.RD	46,945	-			46,945	
Biomedical Research and Research Training	93.859	320,026	-			320,026	43,894
Child Health and Human Development Extramural Research	93.865	9,379,392	-	Lleisensites of Michigan	2004722404	9,379,392	3,144,650
Child Health and Human Development Extramural Research Child Health and Human Development Extramural Research	93.865 93.865	-		University of Michigan University of Michigan	3004733184 SUBK00008038	215,134	-
Child Health and Human Development Extramural Research	93.865			Northwestern University	60046347CRI	59,137	-
Child Health and Human Development Extramural Research	93.865			George Washington University	17-S28	49,311	
Child Health and Human Development Extramural Research	93.865	-		St. Jude Children's Research Hospital	111997019-7661664	12,321	-
Child Health and Human Development Extramural Research	93.865	_		University of California, Los Angeles	2000 G VQ957	10,626	-
Child Health and Human Development Extramural Research	93.865	_		Florida State University	R000002669	36,723	-
Child Health and Human Development Extramural Research	93.865	_		Clear Guide Medical, Inc.	CRI-002	132,451	_
	93.865	_		Cincinnati Children's Hospital Med Ctr	Cincinatti201903	2,245	_
Child Health and Human Development Extramural Research						_,	
Child Health and Human Development Extramural Research Child Health and Human Development Extramural Research	93.865	_	1 340	Boston Children's Hospital	GENED0001623852	1 3/10	_
Child Health and Human Development Extramural Research	93.865 93.865	-		Boston Children's Hospital Medical College of Wisconsin	GENFD0001623852 MCW20190806	1,349 41 006	-
	93.865 93.865 93.865	-	41,006	Boston Children's Hospital Medical College of Wisconsin The University of Chicago	GENFD0001623852 MCW20190806 AWD101148 (SUB00000286)	1,349 41,006 39,653	-

	Assistance	1					Passed to
Federal Program	Listing Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Sub- Recipients
						•	,
Child Health and Human Development Extramural Research	93.865	-		Children's Hospital of Philadelphia	GRT-00000762 / PO# 202280	7,504	-
Child Health and Human Development Extramural Research	93.865	-		Columbia University	1(GG015283-01)	9,977	-
Child Health and Human Development Extramural Research	93.865	-	15,453	Nationwide Children's Hospital	700171-0720-00	15,453	-
Vision Research	93.867	466,838	-			466,838	39,787
Vision Research	93.867		20,832	Virginia Polytec Inst & State University	412524-19859	20,832	
Medical Library Assistance	93.879	800,818	-			800,818	455,221
National Institutes of Health Acquired Immunodeficiency Syndrome Research Loan Repayment Program	93.936		400.000		GB10717.PO#2234098	168.068	
International Research and Research Training	93.989	54,469	100,000	University of Virginia	GB10717.PO#2234096	54,469	22,343
National Cancer Institute	93.969 93.RD	54,469	402.000	Leidos Biomedical Research, Inc	21X125 F1	193,829	22,343
National Cancer Institute	93.ND	34,439,011	9,261,522	Leidos Biomedicai Research, mc	21X125 F1	43,700,533	6,996,693
		34,439,011	9,201,322	=		43,700,333	0,990,093
Office of the Secretary							
COVID-19 Hospital Preparedness Program (HPP) Ebola							
Preparedness and Response Activities	93.817	_	591.120	DC Department of Health	1 U3REP150500-01-01	591,120	_
			591,120	- '		591,120	
				=			
Total Research and Development Cluster		\$36,873,394	\$10,728,779			\$ 47,602,173	\$7,595,970
·				-			
Other Sponsored Programs							
DEPARTMENT OF AGRICULTURE							
Food and Nutrition Service							
Special Supplemental Nutrition Program for Women, Infants,							
and Children	10.557	\$ -		DC Department of Health	CHA2016-000058	\$ 816,433	\$ -
			816,433	_		816,433	
DEPARTMENT OF DEFENSE							
Department of the Army							
Military Medical Research and Development	12.420			DC Breastfeeding Coalition, Inc	DCBC-Long-Title V	210,242	
			210,242	=		210,242	
DEDARTMENT OF HEALTH AND HUMAN OFFINIORS							
DEPARTMENT OF HEALTH AND HUMAN SERVICES							
ARRA	02.740		246 000	E-li-btd I	F-11-14	246 000	
ARRA - State Grants to Promote Health Information	93.719		316,890	Enlightened, Inc.	Enlightened20191025	316,890 316,890	
		<u> </u>	310,090	-		310,090	
Centers for Disease Control and Prevention							
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	_	38 799	Children's Hospital of Philadelphia	GRT-00000783/PO#20224718	38,799	_
Improving the Health of Americans through Prevention and	00.000		00,700	Official of Chicoprasi of Chicagophia	3/1/ 0000// 3//E0ZE // 10	00,100	
Management of Diabetes and Heart Disease and Stroke	93.426	-	38,606	YMCA of Metropolitan Washington	YMCA20190703	38,606	-
-			77,405	· · · · · · · · · · · · · · · · · · ·		77,405	
Office of the Administration for Children & Families							
Family Violence Prevention and Services/Discretionary	93.592	173,483		-		173,483	
		173,483		-		173,483	
National Institutes of Health							
Child Health and Human Development Extramural Research	93.865			University of Alabama-Birmingham	UAB20191022	115,347	96,531
			115,347	=		115,347	96,531
Harling Brown and Advisor Advi							
Health Resources and Services Administration	93.884	209.730				209.730	
Grants for Primary Care Training and Enhancement		,					-
COVID-19 Provider Relief Fund COVID-19 Coordinated Services and Access to Research for	93.498	53,166,873	-			53,166,873	-
Women, Infants, Children, and Youth	93.153	_	12 834	MedStar Health Research Institute	5002075888	12,834	_
Coordinated Services and Access to Research for Women.	33.130	-	12,004	riodar rioda di mondio	11120,0000	12,004	-
Infants, Children, and Youth	93.153	-	77,908	MedStar Health Research Institute	5001465411	77,908	-
HIV Care Formula Grants	93.917	-	234,485	DC Department of Health	20D405 - 21E405	234,485	-
Teenage Pregnancy Prevention Program	93.297	_		DC Primary Care Associates	DCPCA20201030	228,471	-
Maternal Child Health Federal Consolidated Programs	93.110	-	19,734		6028-01	19,734	-
Maternal Child Health Federal Consolidated Programs	93.110	_	67,399		MSVF20210309	67,399	-
Maternal Child Health Federal Consolidated Programs	93.110	-	99,856	, ,	700AU032921	99,856	-
Maternal Child Health Federal Consolidated Programs	93.110	_		Virginia DOH - Commonwealth of Virginia	705AU932817	10,631	-
SubTotal Pediatric Mental Health Care		53,376,603	751,318	· · · · · · · · · · · · · · · · · ·		54,127,921	
				-			

	Assistance Listing					Total	Passed to Sub-
Federal Program	Number	Direct	Pass-Through	Pass-Through Entity	Pass-Through Entity Sponsor Number	Expenditures	Recipients
Health Resources and Services Administration							
Maternal and Child Health Federal Consolidated Programs	93.110	-	75,483	Univ. of North Carolina at Chapel Hill	20201026-1	75,483	-
Emergency Medical Services for Children Access Program	93.127	31,161		_		31,161	
		31,161	75,483	-		106,644	
HIV Emergency Relief Project Grants	93.914	_	475 557	DC Department of Health	20D013	475,557	_
COVID-19 HIV Emergency Relief Project Grants	93.914	_		DC Department of Health	20D050	335.809	_
HIV Emergency Relief Project Grants	93.914	_		DC Department of Health	21E013	165,107	_
HIV Emergency Relief Project Grants	93.914	_		DC Department of Health	HAHSTA2019-000013-21E032	661,525	_
SubTotal HIV Emergency Relief Project Grants			1,637,998	- · ·		1,637,998	
Maternal and Child Health Services Block Grant to the States	93.994		119 007	DC Department of Health	CHA.PSMB.CNMC.122015	118,907	
Maternal and Child Health Services Block Grant to the States	93.994	-		DC Department of Health	CHA2021-000022-000	10,237	-
Maternal and Child Health Services Block Grant to the States	93.994	-		Maryland Department of Health	CH944CSN	5,138	-
Maternal and Child Health Services Block Grant to the States	93.994			Maryland Department of Health	FH868SHN-PHPA-1142.3	100,936	
Maternal and Child Health Services Block Grant to the States	93.994	_		Department of Health and Mental Hygiene	PO#M00P161294	113,903	_
SubTotal Maternal and Child Health Services Block	00.001		110,000	_ Doparation of Floatal and Montal Hygions	1 Offices 10 120 1		
Grant to the State			349,121	_		349,121	
Substance Abuse and Mental Health Services Administration Substance Abuse and Mental Health Services Projects of Regional and National Significance Block Grants for Community Mental Health Services	93.243 93.958	113,498 - 113,498	625,458 625,458	_DC Department of Behavioral Health	CW92996; RM-14-RFP-270-BY4-DJW; RK162513	113,498 625,458 738,956	152,507 152,507
DEPARTMENT OF JUSTICE							
Office for Victims of Crime							
Crime Victim Assistance/Discretionary Grants	16.582	288,506 288,506		- -		288,506 288,506	112,638 112,638
DEPARTMENT OF TRANSPORTATION National Highway Traffic Safety Administration National Highway Traffic Safety Administration (NHTSA) Discretionary Safety Grants	20.614	104,109 104,109	<u>.</u>	_		104,109 104,109	
FEDERAL COMMUNICATIONS COMMISSION Federal Communications Commission COVID-19 Telehealth Program	32.006	813,044 813,044				813,044 813,044	<u> </u>
Total Other Sponsored Programs		\$54,900,404	\$ 4,975,695			\$ 59,876,099	\$ 361,676
Total Federal Award Expenditures		\$91,773,798	\$15,704,474			\$107,478,272	\$7,957,646

1. Basis of Presentation

The accompanying schedule of expenditures of federal awards (the "Schedule") includes the federal award activity of Children's National Medical Center and Subsidiaries ("Children's National") under programs of the federal government for the year ended June 30, 2021. Because the Schedule presents only a selected portion of the operations of Children's National, it is not intended to and does not present the financial position, results of operations, changes in net assets, or cash flows of Children's National. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). CFDA numbers and pass-through entity identification numbers are listed when available.

2. Summary of Significant Accounting Policies

Expenditures reported on the Schedule are reported on the cash basis of accounting. Such expenditures are recognized following the cost principles for Hospitals wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years. Children's National applies its predetermined approved facilities and administrative rate when charging indirect costs to federal awards rather than the 10% de minimus cost rate as described in Section 200.414 of the Uniform Guidance. Indirect costs allocated to such awards for the year ended June 30, 2021 were based on predetermined rates negotiated with Children's National cognizant federal agency, the Department of Health and Human Services.

3. Provider Relief Funds

Children's National was also the recipient of funding under Assistance Listing Number # 93.498, Provider Relief Funds, and as required by the Addendum to the 2020 Compliance Supplement such expenditures have been included in the SEFA for the year ended June 30, 2021.

Part II
Reports on Compliance and Internal Control



Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards

To the Board of Trustees of Children's National Medical Center

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Children's National Medical Center and its subsidiaries ("Children's National"), which comprise the consolidated balance sheet as of June 30, 2021, and the related consolidated statement of operations, changes in net assets, and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated October 8, 2021.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered Children's National's internal control over financial reporting ("internal control") as a basis for designing the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Children's National's internal control. Accordingly, we do not express an opinion on the effectiveness of Children's National's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.



Compliance and Other Matters

As part of obtaining reasonable assurance about whether Children's National's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Pricewaterhorsecroper up

Washington, D.C. October 8, 2021



Report of Independent Auditors on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over Compliance in Accordance with the Uniform Guidance

To the Board of Trustees of Children's National Medical Center

Report on Compliance for Each Major Federal Program

We have audited Children's National Medical Center and its subsidiaries ("Children's National") compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of Children's National's major federal programs for the year ended June 30, 2021. Children's National's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations and the terms and conditions of its federal awards applicable to its federal programs.

Auditors' Responsibility

Our responsibility is to express an opinion on compliance for each of Children's National's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about Children's National's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of Children's National's compliance.

Opinion on Each Major Federal Program

In our opinion, Children's National complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2021.



Report on Internal Control Over Compliance

Management of Children's National is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered Children's National's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of Children's National's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Kricewaterhorsecroper up

Washington, D.C. June 6, 2022

Part III Findings

Children's National Medical Center and Subsidiaries Schedule of Findings and Questioned Costs Year Ended June 30, 2021

Section I - Summary of Auditor's Results

Financial Statements

Type of auditor's report issued:

Unmodified

Internal Control over financial reporting:

Material weakness(es) identified?

Significant deficiency(ies) identified that are not considered

to be material weaknesses?

None reported

Noncompliance material to financial statements noted?

Federal Awards

Internal Control over major programs:

Material weakness identified?

Significant deficiency(ies) identified that are not considered to

be material weaknesses?

None reported

Type of auditor's report issued on compliance

for major programs: Unmodified

Any audit findings disclosed that are required

to be reported in accordance with 2 CFR 200.516(a)?

Identification of major programs:

Name of Federal Program

Federal CFDA Number or Cluster

93.498 COVID-19 Provider Relief

Fund

32.006 COVID-19 Telehealth Program

Dollar threshold used to distinguish between

Federal governmental assistance Type A and

Type B programs: \$3,000,000

Auditee qualified as low-risk auditee? Yes

Children's National Medical Center and Subsidiaries Schedule of Findings and Questioned Costs Year Ended June 30, 2021

Section II – Financial Statement Findings

There are no matters to report.

Section III - Federal Award Findings and Questioned Costs

There are no matters to report.

Children's National Medical Center and Subsidiaries Summary Schedule of Prior Audit Findings Year Ended June 30, 2021

Section II - Financial Statements

There were no audit findings from prior year.

Section III - Federal Awards

There were no findings or questioned costs from prior year.